Yuanliang Xia
Ruohan Yang
Jianshu Zhu1
Hengyi Wang- 1Department of Spine Surgery, The First Hospital of Jilin University, Changchun, China
- 2Cancer Center, The First Hospital of Jilin University, Changchun, China
- 3Department of Gastroenterology, The First Hospital of Jilin University, Changchun, China
Despite advances in cancer treatment, metastatic cancer is still the main cause of death in cancer patients. At present, the treatment of metastatic cancer is limited to palliative care. The abscopal effect is a rare phenomenon in which shrinkage of metastatic tumors occurs simultaneously with the shrinkage of a tumor receiving localized treatment, such as local radiotherapy or immunotherapy. Immunotherapy shows promise for cancer treatment, but it also leads to consequences such as low responsiveness and immune-related adverse events. As a promising target-based approach, intravenous or intratumoral injection of nanomaterials provides new opportunities for improving cancer immunotherapy. Chemically modified nanomaterials may be able to trigger the abscopal effect by regulating immune cells. This review discusses the use of nanomaterials in killing metastatic tumor cells through the regulation of immune cells and the prospects of such nanomaterials for clinical use.
1 Introduction
Although many breakthroughs have been made in the clinical treatment of cancer, metastatic cancer remains extremely difficult to treat and is responsible for more than 90% of cancer deaths (Ganesh and Massagué, 2021). During metastasis, tumor cells penetrate blood vessels or lymph vessels, thus entering into circulation, and later extravasate from capillaries into organs distant from the original cancer site. Tumor cells then adapt to the new environment and develop into metastatic cancers (Mitchell et al., 2021). If a tumor cell metastasizes, the mobility of tumor cells becomes enhanced to the point that the cells easily penetrate the basement membrane and invade surrounding tissues. Sometimes, tumors metastasize despite treatment. At other times, cancer goes undiagnosed until after tumors have metastasized. The main treatment for metastatic cancer is currently palliative, and only 1–10% of metastatic cancers are surgically removed (Pagani et al., 2010). Since it usually cannot be cured, metastatic cancer is the main cause of death in cancer patients (Worrede et al., 2019).
Very rarely, local radiotherapy may cause the resolution of distant metastatic cancers that have not been treated with radiotherapy. This phenomenon is called the abscopal effect. The abscopal effect has been observed during the treatment of breast cancer (Deng et al., 2020a), melanoma (Yang et al., 2020), lung cancer (Perry et al., 2020), pancreatic cancer (Sun et al., 2020a), and other malignant tumors. Although the mechanism of the abscopal effect is still unknown, it has been proven that the abscopal effect is related to the immune mechanism (Ngwa et al., 2018).
Cancer immunotherapy is considered to be a promising strategy for curing metastatic cancer by restoring or strengthening a patient’s immune system (Cable et al., 2021). Unlike radiotherapy and chemotherapy, immunotherapy does not target tumor cells but rather the body’s immune system. Therefore, it is important to understand the relationship between tumor cells and the immune system. The process of adaptive and innate immune systems controlling tumor growth and shaping tumor immunogenicity is called tumor immunoediting (Desai et al., 2022). Immunoediting occurs in three stages: elimination, equilibrium, and escape (Desai et al., 2022). In this process, the immune system acts as a tumor stimulant and tumor suppressor (Saadeldin et al., 2021). During the growth process, tumor cells avoid being killed by the immune system through immune checkpoints, thereby proliferating in large numbers to form cancer (Tsuchiya and Shiota, 2021). After an immunotherapy drug enters the body, it restores the ability of immune cells to recognize cancer cells so that the immune cells kill cancer cells in large quantities to achieve the purpose of treatment. In the last 2 decades, cancer immunotherapy development has included the creation of vaccines, monoclonal antibodies, and small immunomodulatory molecules (Gu et al., 2020). Cancer immunotherapy improves a patient’s immune function and avoid the decline in immune function caused by surgical stress, thereby greatly improving the success rate of surgical treatment.
There are two main purposes of cancer immunotherapy. One is to directly modify immune cells to stimulate the activity of immune cells against tumors, and the other is to reduce the immune suppression of tumor cells or the microenvironment to improve immune cell activity through small molecules or antibody regulation (Cable et al., 2021). However, not all cancer cells are recognized and eliminated by the immune system (Li et al., 2020a). Immune checkpoints expressed on immune cells are a class of molecules that regulates immune activation. Their presence prevents attacking on their own tissues due to the strengthening of the immune system. However, the corresponding receptors are also expressed on tumor cells, which prevents the immune system from killing tumor cells (Zhou et al., 2020a). Although immune checkpoint inhibitors disrupt the balance between immune cells and tumor cells, they also have a serious consequence: immune-related adverse events (irAEs) (Zhou et al., 2020a). IrAEs arise from inflammatory overreactions, usually involving endocrine glands, caused by immune enhancement. These inflammatory overreactions typically induce dermatitis, colitis, and thyroiditis, but they also cause rarer conditions with high mortality, such as myocarditis, myositis, and encephalitis (Hommes et al., 2021). Hence, irAEs are a major obstacle to the widespread use of cancer immunotherapy (Li et al., 2020a; Gomes and Franco, 2022).
Nanomaterials provide new opportunities for improving the efficacy of cancer immunotherapy and reducing its adverse reactions. Because of characteristics such as their size, electrical properties, and shape, nanoparticles are sensitive to chemical modification (Nasirmoghadas et al., 2021). Nanomaterials can penetrate abnormal extracellular matrices, vascular endothelial cells, and complex tumor environments to target tumor cells precisely (Stephen and Zhang, 2021; Thangam et al., 2021). Subsequently, nanoparticles accumulated at a tumor site because of the enhanced permeability retention (EPR) of tumor cells. EPR enhanced the release of nanoparticles around tumor cells, thus greatly improving treatment effectiveness. However, the EPR effect alone cannot accumulate enough nanoparticles because of the high fluid pressure in the tumor stroma (Fu and Xiang, 2020). Nanoparticles can be modified via targeting and biological reactivity (Mitchell et al., 2021), such as the pH response and hypoxia response. Active targeting through surface modification of nanoparticles improved the recognition of tumor sites, thereby increasing the drug concentration in the tumor microenvironment (TME). Chemically modified nanomaterials have good biological tissue compatibility which reduces the concentration of cytokines or deliverables directly leaked into the bloodstream, thereby reducing the occurrence of irAEs (Huang et al., 2021). Although the details of the mechanism of the abscopal effect are unknown, we have found that immune cells play an integral role in the abscopal effect. This review discusses the roles of different types of immune cells and nanomaterials in the abscopal effect (Scheme 1 and Table 1). We look forward to the prospects for the application of the abscopal effect in the clinical treatment of metastatic tumors.
SCHEME 1. Schematic illustration of nanomaterials triggering the abscopal effect in the immunotherapeutic treatment of metastatic cancer. Nanomaterials trigger the abscopal effect in immunotherapy combined with RT and PDT, causing the increase of CD8+ T cells and M1-TAMs in the distant TME and the decrease of Tregs, MDSCs, M2-TAMs, and CAF.
TABLE 1. Nanomaterials trigger abscopal effect for immunotherapy of metastatic cancers.
2 Nanomaterials for regulating dendritic cells to trigger abscopal effect
Dendritic cells (DCs) are important antigen-presenting cells (APCs) in the body. DCs cross-present the antigen of major histocompatibility complex (MHC) class I molecules to activate CD8+ T cells. Tumor-associated antigens (TAAs) can be recognized, processed, and presented by DCs. However, immature DCs produce regulatory T cells (Tregs) to inhibit the activity of T cells (Wculek et al., 2019). Therefore, the number of mature DCs in the body is too low to cause a strong immune response. CD80 and CD86 are markers of mature DC surfaces. Nanomaterials are used to transport tumor antigens, immune adjuvants, and exogenous DCs to tumor-draining lymph nodes (TDLNs), enhance the activity of DCs, and cause a powerful antigen presentation response (Morales-Orue et al., 2019).
2.1 Nanomaterials for recruiting dendritic cells
Antigen presentation in the body is often due to an insufficient number of DCs, which results in a failure to cause more CD8+ T cells to infiltrate the tumor (Gardner et al., 2020). Low immunogenicity and weak immune response limit abscopal effects in the treatment of metastatic tumors. Immunogenic cell death (ICD) promote the recruitment of DCs in metastases. Min et al. (2017) developed several antigen-capturing nanoparticles (ACNPs) based on poly (lactic-co-glycolic acid) (PLGA). Research suggests that positively charged particles were more likely to be captured by DCs. ACNPs delivered TAAs to APCs and promoted DCs trafficking to TDLNs to enhanced antitumor immune responses. In addition to TAAs, high-mobility group box 1 (HMGB1), damage-associated molecular patterns (DAMPs), and histone proteins have also been shown to promote the recruitment of DCs (Ren et al., 2018; McCaw et al., 2019; Wang and Zhang, 2020). Natural compounds often act as carriers to transport these substances around tumors. Because of its large surface area, large pore size, multifunctional surface modifiability, and biodegradability, silica has been widely used for drug delivery (Nguyen et al., 2020a). Deng et al. (2020b) developed silica mesoporous nanotechnology for the delivery of nanovaccines for metastatic cancer immunotherapy. The silica nanoparticles enhance the recruitment of DCs. However, whether the nanoparticles trigger the abscopal effect has not been verified.
Tumor cells are surrounded by a hypoxic environment, which is conducive to tumor cells escaping attack by the immune system (Fu and Xiang, 2020). Therefore, increasing the amount of oxygen in the tumor environment is an effective way to induce ICD and activate DCs to produce powerful anti-tumor effects. Gold nanocages (AuNCs) have attracted considerable attention because of their hollow porous structures and controllable optical performance. Liang et al. (2018a) encapsulated manganese dioxide with AuNCs (AuNC@MnO 2) for targeting tumor-associated macrophages (TAMs) for oxygen production. AuNC@MnO 2 was prepared by mixing AuNC and polyethylene glycol (PEG) in a potassium permanganate solution by magnetic stirring. With an average size of 91 nm and a surface charge of + 5.6 mV, AuNC@MnO2 had the advantage of reactive oxygen species (ROS) responsiveness to generate oxygen around the tumor. The nanocages elicited ICD by provoking dying tumor cells to induce enhanced exposure and release of DAMPs, such as calreticulin, adenosine triphosphate (ATP), and HMGB1. DAMPs then promoted the recruitment of DCs and increased the antigen engulfment and presentation, followed by prominent activation of effector cells (e.g., CD8 T cells, CD4 T cells, and NK cells) for inhibition of primary tumor and lung metastases. AuNC@MnO 2 combined with photodynamics up-regulated the expression of CD80 and CD86 up to 7.5% and reduced the number of lung metastases in tumor-bearing mice (Liang et al., 2018a). Yang et al. (2020) explored PEG cationic peptides to self-assemble into pH-responsive nanovesicles. PEG nanovesicles with a hydrodynamic diameter of 55 nm. In vitro experiments showed that PEG nanovesicles were endocytosed by tumor cells within 4 h. Encapsulation of photosensitizers into PEG nanovesicles generated ROS within tumors to induce tumor cell death. In tumor-bearing mice, PEG nanovesicles significantly inhibited the growth of primary and distant tumors within 17 days. Human serum albumin (HAS) shows natural biocompatibility, excellent stability, and positive tumor targeting ability. Chen et al. (2018) utilized reduced HAS and hemoglobin (Hb) through intermolecular disulfide hybridization to obtain hybrid protein oxygen carrier (HPOC) nanoparticles. The advantage of HPOC was that Hb’s own oxygen-carrying ability provided oxygen to the hypoxic environment of tumor cells and improved the treatment efficiency. In another study, Zhou et al. utilized maleimide liposomes to deplete intracellular glutathione. Liposomes remodeled TAMs to promote DCs recruitment (Zhou et al., 2020b).
CCL21 is a chemokine that promotes the recruitment of DCs (Hu et al., 2020). Owen et al. developed a hydrogel made of PEG-polylactic acid (PLA) for carrying CCL21 to promote DCs recruitment (Fenton et al., 2019). The advantage of hydrogel was that after injection into the mouse, CCL21 was released within 48 h to recruit DCs to the injection site. In another study, protamine sulfate loaded with seaweed shown high loading rate of CCL (Poelaert et al., 2020). Protamine sulfate acts as a polycation, stabilizing alginate nanoparticles into polyelectron complexes. Intratumoral injection of nanoparticles caused neuroblastoma to decline and improved the long-term immune effect of mice (Poelaert et al., 2020). However, no instances of the abscopal effect being triggered by CCL21 loaded on nanomaterials have yet been reported. We believe that nanomaterials to induce CCL21 to enter the metastatic tumor site to recruit DC is a promising method for metastatic tumor treatment.
2.2 Nanomaterials for eliciting DC maturation
Immature DCs cause T cells to be unresponsive to tumors and lead to immune tolerance (Dudek et al., 2013). Therefore, the maturation of DCs is crucial to achieving the abscopal effect in immunotherapy. Because of the presence of transforming growth factor-β (TGFβ) and interleukin 10 (IL10), the number of DCs in tumor patients is abnormal (Brown et al., 2001). Toll-like receptors (TLRs) are an important class of protein molecules involved in non-specific immunity. TLR9 is mainly expressed in B cells and plasmacytoid dendritic cells (pDCs) (Krieg, 2007). The activation of TLR9 on pDCs has a variety of effects, such as the expression of Interferon-γ (IFN-γ), Th1-type cytokines (tumor necrosis factors-α, IL-2), TNF-related apoptosis-inducing ligand (TRAIL), and co-stimulatory molecules (CD80, CD86) (Suek et al., 2019). TLR7 and TLR9 have been proven to be related to the maturity of DCs (Leong et al., 2019).
Natural polysaccharides are polymers with good biological safety and various biological functions (Zhu et al., 2016; Yu et al., 2018). Natural polysaccharide nanoparticles carrying TLR agonists caused more DCs activation (Pang et al., 2019). Although the application of TLR agonists has a good effect, it once caused obvious inflammation. Darling et al. (2020) explored acetic anhydride nanoparticles with a mixture of 3,6-dioxaoctante (CPTEG) and 1,6-bis (p-carboxyphenoxy) hexane (CPH) by a molar ratio of 20:80. The average particle size of the nanoparticles was approximately 200 nm. Acetic anhydride nanoparticles provided antigen delivery and DCs activation while avoiding the extensive inflammatory response usually associated with traditional adjuvants (Darling et al., 2020). Nanomaterials carrying TLR agonists have been reported to enhance DCs activation and trigger the abscopal effect (Cano-Mejia et al., 2020; Ni et al., 2020; Perry et al., 2020; Luo et al., 2021). For example, as a class of molecular nanomaterials, cationic nanoscale metal–organic frameworks (nMOFs) are suited for biomedical applications because of their crystallinity, tuneability, and porosity (Ni et al., 2020). nMOFs had emerged as novel nanophotosensitizers for photodynamic therapy (PDT) with high photosensitizer (PS) loadings, enhancing the abscopal effect of PDT triggering. Prussian blue (PB) also shows good biocompatibility and is widely used in biomedicine. Rohan et al. developed PB nanoparticles for the delivery of CpG and promoted the maturation of DCs in neuroblastoma (Cano-Mejia et al., 2020). PB nanoparticles alter the presence of immunomodulatory receptors and ligands on the treated tumor cells and generates an abscopal effect. PB exhibits pH-dependent biodegradability, mitigating concerns over long-term persistence and toxicity within the body (Cano-Mejia et al., 2020). The study found that the local release of ROS from the tumor also promoted the maturation of DCs. Wang et al. (2021a) devoloped light-activable immunological adjuvant (LIA) loaded with chlorin e6, after being internalized by tumor cells in a mouse model of breast cancer. LIA produced ROS under light to induce tumor cells to released antigens and also promoted DCs maturation.
Radiotherapy (RT) can break the DNA double bond of tumor cells, release TAAs, and cause tumor cells to produce ICD. RT has been widely used clinically. However, RT is normally used for localized treatment rather than to treat metastatic cancer, and it is not safe for certain areas of the body. Chen et al. explored cisplatin loaded within PLGA-graft-methoxy PEG complex nanoparticles (CDDP-NPs) (Figure 1) (Wang et al., 2021b). Platinum crosslinks the DNA double strand, reducing the stability of DNA by a process called DNA platination. This nanomaterial enhanced the body’s tolerance to radiation doses and caused more DNA damage in tumor cells. CDDP-NPs resulted in greater DNA platinization compared to CDDP at 24 h (51.02 × 10–3 pg Pt per ng DNA), 48 h (38.80 × 10–3 pg Pt per ng DNA), and 72 h (14.24 × 10–3 pg Pt per ng DNA) (Figure 1B). Figure 1B The nanoparticles extended the residence time of platinum-based chemotherapeutics around the tumor but did not damage the cells of the whole body (Figure 1C). The combined application of cisplatin nanoparticles and radiotherapy increased the expression of CD80 in distant tumors (Figure 1D), boosted the abscopal effect and delayed the progression of primary and distant tumors (Figures 1E,F). However, CDDP-NPs induced hematopoietic suppression and peripheral cytopenias (Wang et al., 2021b). This may be detrimental to the application of CDDP. Therefore, further research is needed to reduce its side effects.
FIGURE 1. Cisplatin nanoparticles boost abscopal effect. (A) Structure of cisplatin (CDDP) loaded poly (l-glutamic acid)-graft-methoxy poly (ethylene glycol) complex nanoparticles (CDDP-NPs). (B) The Pt content in the tumor DNA of differentially treated mice on the basis of CDDP for 24, 48, and 72 h. (C) Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine (CREA) in the indicated groups on day 10. (D) The population of activated DCs in tumors was evaluated on day 9 in vivo. (E) The tumor volume of primary tumor. (F) The tumor volume of distant tumor. Reproduced with permission from (Wang et al., 2021b).
CD40/CD40L is another pathway that causes the maturation of DCs. CD40 increase the expression of immunoglobulin superfamily co-stimulatory molecules such as CD80 and CD86 (Vonderheide, 2020). CD40 signaling occurs through two adaptor proteins, TNFR-related factor (TRAF) and Jak family kinase 3 (JAK3). These proteins activate various signaling pathways, including MAPK, PI3K, and NF-kβ, which in turn cause DCs to mature. It has been confirmed that CD40 agonists boost abscopal effects by activating DCs (Wood et al., 2020). Although CD40 affects the maturation of DCs, CD40 stimulation alone does not enable mice to obtain long-term immunity but rather produces ineffective cytokines and specific T cells (Lau et al., 2020). The combination of CD40 antibodies and TLR agonists is generally more effective. Liu et al. developed nanofluidic drug-eluting seeds (NDES) for the delivery of CD40 antibodies and TLR agonists into tumors (Liu et al., 2020). The nanochannel of NDESs was 150 nm, and intratumoral injection of NDESs continuously and slowly released CD40 as long as 14 days. In combination with external radiation therapy, NDESs enhanced the abscopal effect and reduced the chance of metastasis by promoting the maturation of DCs.
In conclusion, some nanomaterials targeting DCs exert anti-tumor effects. Nanomaterials located with TLR agonists not only treat existing tumors but also play a role in preventing tumor metastasis. Not only that, nanomaterials have been proved to good biological tissue compatibility and targeting. Many effects, such as regulate DC maturation and activation, have been shown to exist simultaneously. These findings have opened up new avenues for progress in tumor treatment.
3 Nanomaterials for regulating T cells to trigger abscopal effects
Once the MHC on a DCs binds to a T cells receptor, the T cells will be activated and differentiate into effector T cells. Effector T cells are mainly composed of CD4+ effector T cells and CD8+ T cells. CD8+ T cells are the main anti-tumor cells in the body (Gardner et al., 2020). Subsequently, CD8+ effector T cells circulate systemically, infiltrate tumor lesions through interstitial blood vessels, and kill metastatic tumor cells (Tsuchiya and Shiota, 2021). However, many inhibitory factors in the TME hinder T cells’ function.
3.1 Nanomaterials with blocking immune checkpoints
Immune checkpoints are inhibitory regulatory molecules in the immune system that are essential for maintaining self-tolerance and preventing autoimmune reactions. Immune checkpoints expressed on immune cells inhibit the function of immune cells so that the body does not produce enough effective anti-tumor immune responses. The immune checkpoint blockade (ICB) enhances anti-tumor activity by disrupting inhibitory T cells signaling (Shi et al., 2020). Programmed cell death protein 1 (PD-1) is an important immunosuppressive transmembrane protein expressed on the surface of T cells. PD-L1 is a ligand of PD-1. The combination of PD-1 on the surface of T cells with PD-L1 will transmit inhibitory signals and reduce the proliferation of CD8+ T cells in lymph nodes. One of the important mechanisms by which tumor cells evade the attack of immune cells is by expressing PD-L1 (Han et al., 2020). Metastatic cancer cells express more PD-L1 than normal tissue cells (Eckert et al., 2018). Blocking the PD-1/PD-L1 signaling pathway can thus enhance the killing of metastatic tumors by CD8+ T cells. In addition, cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a leukocyte differentiation antigen, a transmembrane receptor on T cells, and it shares the B7 molecular ligand with CD28. CD28 is a transmembrane protein on the surface of T cells. The APC surface expresses B7.1 (CD80) and B7.2 (CD86) ligands. The combination of CD28 and B7 molecular ligands can activate T cells. CTLA4 has a structure homologous to CD20 that can compete with CD28 for B7 ligands, resulting in insufficient T cell activation (Hosseini et al., 2020). Although ICB has achieved good results, it only works on tumor cells that have been pre-infiltrated by T cells (Spranger and Gajewski, 2018). In metastatic tumors, insufficient T cell infiltration has become a major obstacle to treatment. Therefore, how to induce the infiltration of T cells into metastatic TME and increase T cells’ activity have emerged as key problems in the pursuit of curing metastatic cancer.
Blocking immune checkpoints enables the immune system to recognize and attack metastatic tumor cells. However, the application of ICB alone cannot trigger the abscopal effect to eliminate metastases. The body needs to activate the immune system to induce tumor cells to produce ICD. Nanoparticles induce ICD to expose the tumor to more TAAs when nanoparticles enter the periphery of the tumor. With the application of ICB, more T cells can infiltrate the tumor. Huang explored a celastrol (CEL) nanoemulsion (Qiu et al., 2021). CEL is recognized for its anti-inflammatory effects via suppressing macrophage M1 polarization. In addition, nanoparticles caused an inflammatory response, promoted the recruitment of NK cells in metastatic tumors, and activated tumor-specific T cells to control metastatic tumors. In an experiment involving intravenous injection of CEL nanoemulsion and intraperitoneal injection of anti-PD-L1 in tumor-bearing mice, the CEL nanoemulsion/anti-PD-L1 treatment exhibited a good killing effect, inducing nearly 90% of the total cell apoptosis in treated tumors, with nearly 15-fold or 10-fold more apoptotic cells compared to the control, and anti-PD-L1-treated tumors. After the application of anti-PD-L1, the growth of the primary tumor and the distant tumor was significantly inhibited. Instead of delivering anti-PD1 directly, experimental mice are usually injected intraperitoneally with anti-PD1 to block ICB. Nanoparticles can synergize with ICB to induce stronger abscopal effects after intravenous injection. For examples, upconversion nanoparticles (UCNPs), ROS-sensitive lipid-polymer hybrid nanoparticles, PB nanoparticles and nanoliposomes loaded with pheophorbide A (PhA) have been shown to produce long-term immune memory effects and further enhance the ICB therapeutic outcome (Xu et al., 2017; Hu et al., 2019; Zhou et al., 2020c; Hwang et al., 2020). Tandem peptide nanocomplex (TPNC) and copper chalcogenide nanoparticles carrying CpG can also enhance the therapeutic effect of ICB (Buss and Bhatia, 2020; Cao et al., 2020).
3.2 Nanomaterials for blocking the indoleamine 2, 3-dioxygenase pathway
Indoleamine 2, 3-dioxygenase (IDO) is one of the body’s main oxygenases for tryptophan metabolism. It can reduce cellular energy levels, prevent immune cell maturation, and induce T cell apoptosis (Heidari et al., 2020). IDO is the rate-limiting enzyme that metabolizes tryptophan to kynurenine in the body, which regulates the level of metabolism in the body and leads to immune tolerance in the body. IDO is expressed in the cytoplasm of a variety of cells in the TME, DLNs, and peripheral blood. IDO mainly affects the anti-tumor effect of T cells in the following ways. 1) The expression of IDO in tumors is related to the expression of forkhead box P3 (FoxP3) positive T-regs and monocytes in tumor infiltration, and these cells will negatively regulate CD8+ T cells in primary tumors and metastases (Meireson et al., 2020). 2) IDO down-regulates the expression of T cells receptors and inhibits T cells proliferation. 3) IDO also affects the function of T cells by reducing the expression of CD107a and granzyme B. 4) IDO also promotes the production of tumor blood vessels (Prendergast et al., 2018). 5) IDO is closely related to the expression of PD-1 and PD-L1 (Dill et al., 2018; Ye et al., 2018). Recent studies have confirmed that the combination of CTLA-4 and CD80/CD86 on APC can induce IDO expression (Walker and Sansom, 2015). IFN-γ produced by T cells and NK cells induces TRC to enter a dormant state through the IDO-Kyn-AhR-p27 cascade, thereby allowing tumor cells to escape immunity (Liu et al., 2017). Therefore, IDO inhibitors have become a hotspot in tumor immunotherapy.
Most IDO inhibitors cannot function effectively due to their short half-life and poor tumor accumulation (Kuang et al., 2018). Chen et al. (2020) encapsulated indocyanine green (ICG), a photosensitizer, into chitosan nanoparticles (ICG-NPs) (Figure 2A). The zeta potential of ICG-NPs was 47.2 ± 0.3 mV, and the particle size was approximately140 nm. ICG-NPs delivered photosensitizers into tumor cells and effectively regress 80% of tumors in melanoma mice. Sun et al. (2020a) prepared gemcitabine and polydopamine nanoparticles (PGEM/dp-16 NPs) by thin-film aqueous method for loading NLG919, a potent IDO inhibitor. In vitro experiments demonstrated that PGEM/dp-16 NP-mediated photothermal therapy (PTT) could efficiently kill cancer cells within 5 min (Figure 2B). IDO inhibitors increased more CD8+ T cells after releasing outside tumor cells and reduced T-reg infiltration in the TME. In addition, it can significantly reduce the tumor volume of metastatic tumor models (83%) and reduce the risk of lung metastasis (Figures 2D,E). However, in the early metastatic stage, PGEM/dp-16 NPs did not exhibit a good abscopal effect to regress distant tumors (Sun et al., 2020a). To enhance the delivery of IDO inhibitors, Li et al. (2020b) developed a mesoporous silica nanoparticle (MSN) for the delivery of doxorubicin (DOX) and IDO inhibitors. MSNs were about 70 nm in diameter and released IDO inhibitors outside tumor cells and transport DOX into tumor cells. After systemic administration to tumor-bearing mice, MSN was found to induce tumor regression and reduce the number of lung metastases. To increase the targeting of nanoparticles, Liu et al. (2019) co-encapsulated porphyrin-phospholipid conjugates and IDO inhibitors to form redox-activated liposomes. Redox-activatable liposomes prolonged the existence time of IDO inhibitors in the bloodstream, better target tumor cells. The advantage of redox-activatable liposomes was their ability to released IDO inhibitors in the reducing TME, shown the highest efficacy in inhibiting primary and distant tumors and prevented breast cancer metastasis in an orthotopic 4T1 tumor-bearing mouse model (Liu et al., 2019).
FIGURE 2. Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-PTT. (A) Schematic illustration of the mechanism of anti-tumor immunity. (B) The fluorescence images of PANC02 cells co-stained with fluorescein diacetate (FDA, green) and propidium iodide (PI,red) after various treatments. (C) Percentages of CD8 + T within the gated CD45+ population in primary tumors. (D) The tumor volume of primary tumor. (E) The tumor volume of distant tumor. Reproduced with permission from (Sun et al., 2020a; Chen et al., 2020).
3.3 Nanomaterials for delivering cytokines
Cytokines are small-molecule proteins secreted by cells that have the functions of mediating and regulating immune processes. According to their structure and function, they are divided into interleukins, interferons, TNF, colony-stimulating factors, chemokines, growth factors, and so on. This article mainly introduces several cytokines related to the abscopal effect of killing metastatic cancer cells.
IL-12 is a potent pro-inflammatory factor produced by APCs, which induces and enhances cell-mediated immune responses. The target cells of IL-12 are NK cells and T cells, which promote the proliferation of T cells and NK cells and induce the production of γ-IFN. In addition, IL-12 increases the expression of human lymphocyte antigen (HLA) by tumor cells and promote the combination of T cells and antigens to exert anti-tumor effects (Yue et al., 1999). Although IL-12 plays an important role in anti-tumor activity, very small doses of IL-12 cause systemic toxicity (Robertson et al., 1999). The current obstacle to IL-12 treatment is the inability to effectively deliver IL-12 to tumors without causing an increase in systemic IL-12 (Nguyen et al., 2020b). Yao et al. explored a novel photothermal agent and IL-12 gene fragment co-delivery nanoparticle (CSP) (Lin et al., 2021). The hydrodynamic size of nanoparticles increased from 118 to 157 nm. Studies have found that CSP@IL-12 nanocomplex synthesis increased the level of IL-12 expression in B16F10 cells. When CSP@IL-12 nanocomplex was combined with PDT, CSP@IL-12 nanocomplex increased the expression of IL-12 gene fragments in tumors, thereby significantly increased the amount of IL-12 in the TME. CSP@IL-12 nanocomplex achieved good tumor regression, and produced the abscopal effect to kill metastatic cancer cells. In order to increase the targeting of nanoparticles to TME, Sun et al. (2020b) designed a novel nanosystem based on TAM charge-reversal polymetformin (PMet), which simultaneously delivered DOX and IL-12 gene fragments. The mechanism of increased TAM targeting lies in the synergistic encapsulation of thiolated hyaluronic acid (HA-SH) into PMet nanosystems to facilitate precise TME targeting. PMet nanoparticles with an average particle size of 192.3 nm showed improved anti-tumor and antimetastatic activity in a mouse model of breast cancer lung metastasis. However, PMet nanoparticles formed aggregates with serum components shortly after incubation. Such aggregates do not seem to be conducive to the long-term antitumor effect of PMet nanoparticles in vivo. In order to further improved the carrying efficiency, Antonio et al. used Layer-by-layer (LBL) assembly to load IL-12 gene fragments onto the surface of glyceroliposomes with poly-L-arginine (PLR) as a polymer coating for reducing systemic toxicity (Barberio et al., 2020). For the external layer, both hyaluronic acid (HA) and poly-l-glutamic acid (PLE) were chosen to produce a dense negative charge. LBL-NPs were 80–120 nm in diameter, and each LbL-NP contained approximately 50 IL-12 molecules. Reduction of IL-12 systemic toxicity and induction of abscopal effects were observed in a ovarian cancer tumor-bearing mice.
IL-2 is another cytokine of the interleukin family, also known as T cells growth factor. IL-2 binds to the IL-2 receptor and affects the proliferation, activation, and differentiation of immune cells (Raker et al., 2020). IL-2 has a certain effect on the proliferation of effector T cells, but it is not necessary for the proliferation of effector T cells. Different doses of IL-2 activate different types of immune cells (Raker et al., 2020). In the presence of low-dose IL-2, IL-2 receptors are mostly activated on Tregs; under medium- and high-dose IL-2 conditions, also lower-affinity IL-2 receptors are bound on effector T cells and NK cells (Raker et al., 2020). Therefore, it seems advantageous to maintain high-dose IL-2 levels in the tumor microenvironment. However, excessively high doses of IL-2 regulate tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor (Liu et al., 2021). The short lifespan of IL-2 has also become an obstacle to its use as an immunotherapy drug. To increase the half-life of IL-2 in the body, Votavova et al. (2015) explored combining IL-2 gene fragments with a co-polymer to make it a nanoparticle with an IL-2 agonist effect. Each IL-2 molecule carries 2 methacrylamides (HPMA). This co-polymer can prolong the half-life of IL-2 in the body and effectively control the concentration of IL-2, thereby avoiding the toxicity caused by excessive IL-2 concentration (Votavova et al., 2015). However, the biological activity of IL-2 modified by this co-polymer is weaker than that of normal IL-2. Although it causes the increase of CD8+ T cells and NK cells in the body, the anti-tumor effect needs to be further improved. Yin et al. co-delivered DOX and IL-2 with chitosan nanoparticles (Wu et al., 2017). Chitosan nanoparticles carrying DOX and human recombinant IL-2 solved the toxicity problem of DOX and IL-2 in the bloodstream. However, it has been found that local delivery of IL-2 increases the expression of T-regs, which was detrimental to the antitumor effect (McHugh et al., 2015; Horwitz et al., 2019). To reduce the local effect of T-regs on the antitumor effect without reducing the effect of IL-2, Jason et al. developed nanoscale liposomal polymeric gels (nLGs) for the delivery of IL-2 and TGF-β receptor-I inhibitors (Park et al., 2012). Elimination of TGF-β reverses TAM immunosuppression and enhanced antitumor immune responses. After 3 days of systemic administration, nLGs were able to maintain 38% ± 8% of initial concentrations in a mouse model of metastases. This indicates that nLGs not only increase the concentration and half-life of IL-2, but also effectively reversed the immunosuppressive environment. In another study, Sharma et al. (2020) used PEG and IL-2 to prepare a prodrug of IL-2 that could directly eliminate T-regs in TME. It selectively induced the release of cytokines on tumor-infiltrating T cells and selectively depleted Tregs in the tumor without causing changes in the number of Tregs outside the tumor (Sharma et al., 2020). Although this treatment has a good limiting effect on tumors, it has not been reported to have an abscopal effect on metastases.
Although there are not many studies on cytokine-regulated immunotherapy to trigger the abscopal effect, the effectiveness of cytokines is obvious. Nanomaterials can enhance cytokine targeting and dose sensitivity. We believe that nanomaterials to regulate cytokines to trigger the abscopal effect will have very good application prospects.
3.4 Nanomaterials for depleting tregs
Tregs are cells that play an inhibitory role in the body. For example, Tregs produce immune tolerance by producing large amounts of TGFβ, IL10, IL35, and other factors (Schmidt et al., 2012). Tregs are produced by continuous antigen stimulation of T cells and are induced by TGF-β, and they exert their effects through TGF-β and other cytokines (Turner et al., 2020). After Tregs are activated, cytokine immunosuppression is non-antigen specific. This non-antigen specificity is not restricted by MHC and can inhibit the proliferation and activation of CD8+ T cells. This is the main reason for limiting distant tumor suppression (Legoux et al., 2015). The γ-IFN produced when T cells exert anti-tumor activity can regulate the development and differentiation of Tregs through interferon regulatory factor 4 (IRF4) (Alvisi et al., 2020). In the context of γ-IFN and TGF-β, peripheral CD4+CD25-T cells can be transformed into CD4+CD25 + Treg, accompanied by the up-regulation of Foxp3. CD25 is the receptor of IL-2. Tregs in tumors up-regulate the expression of the IL-2 receptor, inhibit other immune cells from binding to IL-2, and affect the activation of immune cells (DeOca et al., 2020).
An increase in the number of effector T cells will also cause an increase in the number of Tregs. Besides T cells, the function of APCs is also regulated by Tregs. The combination of Tregs and APC can cause surface molecules to peel off and inhibit the antigen presentation of APC cells (Raffin et al., 2020). DCs produce CCL22, bind to the CCR4 receptor, and regulate the migration of Tregs to the TME (Röhrle et al., 2020). Therefore, how to reduce the number of Tregs around the metastatic tumor has become a key problem in the field of tumor immunotherapy.
In addition to the aforementioned cytokine delivery that eliminates T-regs, direct depletion of T-regs in TME also enhance antitumor responses. Kohno et al. (2020) injected diphtheria toxin into tumor cells to deplete Tregs in the spleen, blood, and lymph nodes of DEREG transgenic mice after irradiation, and the survival time of the mice was prolonged. Diphtheria toxin depleted Foxp3+ Tregs in these transgenic mice. This reduces T-reg in the distal tumor microenvironment and enhances the distant effect triggered by the immune response. Depletion of Tregs induced the activation of systemic T cells and produce cytokines and cytolysins. Although depletion of Tregs throughout the body caused tumor cell regression, it also caused severe inflammation in the body (Lui et al., 2020). In one study, a homemade curcumin analog (CA) was encapsulated in α-lactalbumin (α-LA), and the Treg cell-specific antibody (mAb), as a therapeutic agent, was linked to the drug-loaded protein via matrix metalloproteinase-responded peptide (P) to form CA@α-LA-P-mAb NPs (Du et al., 2020). The diameter of CA@α-LA-P-mAb NPs were 175.0 ± 8.4 nm. It was shown that CA@α-LA-P-mAb NPs could mediate mitochondrial apoptosis, but CA@α-LA-P-mAb NPs had no toxicity to normal cells. Under the CA@α-LA-P-mAb, tumors were dramatically reduced, and the tumor inhibition rate was 75.0%. In conclusion, targeting the depletion of Tregs delayed tumor growth. In addition, increasing the ROS of TME reduced the production of T-regs. Catalase loaded onto polydopamine -ICG nanoparticles and pH-sensitive polymethacrylate-coated CaO2 nanoparticles enhanced ROS generation in tumors, resulting in the reduction of intratumoral FOXP3+ regulatory T cells (Table 1) (Nicholas et al., 2021; Sun et al., 2021).
4 Nanomaterials for regulating myeloid-derived suppressor cells to trigger abscopal effect
Myeloid-derived suppressor cells (MDSCs) in the body mainly exist in the bloodstream and around tumors. They can be divided into MDSCs from mononuclear sources (i.e., M-MDSCs) and those from granulocyte sources (i.e., G-MDSCs). G-MDSCs mainly exist in peripheral lymphoid organs, and M-MDSCs mainly exist around tumors. M-MDSCs promote tumor cells invasion, angiogenesis, and metastasis formation and inhibit anti-tumor immunity (De Cicco et al., 2020). MDSCs in the bone marrow are recruited to peripheral lymphoid organs and tumor sites through growth factors secreted by cancer cells (Law et al., 2020). MDSCs progenitor cells are usually necessary to restore tissue homeostasis after infection and traumatic stress. However, MDSCs cannot differentiate into immunogenic DCs or inflammatory macrophages in the TME. Once recruited, MDSCs promote the formation of abnormal tumor blood vessels, destroy the antigen presentation of DCs, inhibit the functions of T cells and NK cells, and polarize TAMs into the M2 phenotype (Goldszmid et al., 2014; Kumar et al., 2016a). In addition, MDSCs reduce the secretion of γ-IFN by secreting IL10 and TGF to recruit Tregs (Sacchi et al., 2018). In recent years, inhibiting MDSCs has emerged as a potentially promising cancer treatment. Approaches include 1) depleting MDSCs, 2) inhibiting the recruitment of MDSCs to the tumor site, 3) inhibiting the inhibitory activity of MDSCs, and 4) promoting the differentiation of MDSCs (De Cicco et al., 2020).
4.1 Nanomaterials for polarizing myeloid-derived suppressor cells
MDSCs are immunosuppressive cells, mainly including immature monocytes and granulocytes. Immature DCs are also a type of MDSCs. Studies have shown that ROS inhibited MDSCs differentiation (Kusmartsev and Gabrilovich, 2003). All-trans retinoic acid down-regulated the effect of ROS and regulated MDSCs differentiation by up-regulating glutathione (GSH) synthesis and down-regulating ROS content in cells (Nefedova et al., 2007). Studies have found that all-trans retinoic acid reduces MDSCs and improves the effect of immunotherapy treatment for sarcoma (Kusmartsev et al., 2003; Long et al., 2016).
The hypoxic tumor environment leads to the down-regulation of STAT3, which controls the differentiation of MDSCs to TAMs (Kumar et al., 2016b). Elimination of STAT3 expression by conditional knockout mice or selective STAT3 inhibitors can significantly reduce MDSCs expansion and T cells responses (Kortylewski et al., 2005). As an inhibitor of STAT3, docetaxel reduces tumor-induced MDSCs, TAMs, and endothelial cells infiltration into tumors, thereby inhibiting angiogenesis, tumor growth, and metastasis (Tsai et al., 2017). Interestingly, it has been clinically reported that docetaxel administered as a chemotherapeutic drug can trigger the abscopal effect to promote the regression of urothelial cancer (Ishiyama et al., 2019). PEGylated liposomes loaded with DOX nanoparticles carrying docetaxel increased the intratumoral concentration of the drug and reduce the concentration of the drug in the bloodstream, thus reducing the toxic side effects of the drug (Atrafi et al., 2020). PEGylated liposome loaded with doxorubicin was the first FDA-approved nanomedicine. It has been shown in phase one clinical trial that it increased plasma concentrations. In addition, there have been related reports on the role of TLRs and granulocyte-macrophage colony-stimulating factor (GM-CSF) in inducing MDSCs differentiation (Shirota et al., 2012; Kong et al., 2020; Long et al., 2020; Zamorina et al., 2020). These reports produced antitumor effects in primary tumor models. However, there are not many studies on the targeting of nanomaterials for MDSCs-induced immunotherapy to trigger the abscopal effect.
4.2 Nanomaterials for blocking MDSC infiltration
Many pathways affect MDSCs apoptosis. IL4Rα and STAT6 play important roles in the activation of MDSCs and the maintenance of theirs inhibitory activity by regulating the expression of ARG1 and the secretion of TGF-β (Roth et al., 2012). IL4 regulates ARG-1 transcription through the IL4Ra-STAT6 pathway and increases L-arginine depletion, reducing T cells’ survival rate (Grzywa et al., 2020). RNA aptamer specifically recognizes IL4Ra allowing it to target MDSCs, and induces MDSCs apoptosis by blocking signals from IL4Ra (Roth et al., 2012). However, IL4Ra is also expressed on B cells, T cells, and TAMs. Therefore, RNA apoptosis is not very specific to MDSCs apoptosis.
CXCR2 is the G protein-coupled receptor of human (C–X–C motif) chemokine. The expression of CXCR2 in cancer cells drives proliferation, invasion, and migration (Steele et al., 2016). However, CXCR2 is expressed on MDSCs but less expressed on tumor cells (Steele et al., 2016). Knocking out CXCR2 or CXCR2 inhibitors generate more T cells and reduce pancreatic cancer metastasis (Steele et al., 2016; Sun et al., 2019). Therefore, exploring nanoparticles to inhibit MDSCs by targeting CXCR2 inhibitors in tumors is a promising cancer treatment.
Tumor hypoxia has also been shown to recruit MDSCs. Although chemotherapeutic drugs can directly clear MDSCs, clearing MDSCs in normal tissues has the risk of inducing immunodeficiency (Zuo et al., 2020). Therefore, targeted elimination of MDSCs in the TME is a promising therapeutic modality. In a study, silica nanoparticles carrying mitochondrial respiration inhibitors improved hypoxia around tumors. The silica nanoparticles blocked the infiltration of MDSCs into the tumor and enhanced the anti-tumor effect (Tuettenberg et al., 2016; Zuo et al., 2020). He et al. developed nanoparticles (PLT NPs) using phenylboronic acid-modified low molecular weight heparin and tocopheryl succinate (Lu et al., 2021). The average particle size of PLT-NPs were 140 nm. PLT NPs could significantly improve the immune microenvironment of pancreatic tumors and inhibited spontaneous metastases. PLT NPs will not damage red blood cells as the dose increases. When such nanoparticles were injected into the body, it was observed that nanoparticles accumulated at the tumor site and reduced the infiltration of MDSCs around the tumor (by 5.02%) on the 18th day. Additionally, phenylboronic acid-modified nanoparticles reduced the number of metastases, and non-toxic heavy metal-oxo cluster secondary building units (SBUs) and photosensitizing bridging ligands enhanced the immunotherapy of metastatic cancers (Ni et al., 2019).
Although MDSCs have been demonstrated as suppressor cells in TME. However, current studies on regulating the abscopal effects of MDSCs are uncommon. This may be related to the potential of MDSCs to differentiate into other cells. The mechanism of the abscopal effect remains elusive. Therefore, it seems difficult to regulate MDSCs alone to trigger abscopal effects.
5 Nanomaterials for regulating targeting tumor-associated macrophages to trigger abscopal effect
Macrophages play an indispensable role in cancer immunotherapy. Macrophages are mainly divided into M1 type and M2 type (Mantovani and Locati, 2013). M1-type macrophages activate CD8+ T cells and NK cells by presenting TAAs and producing cytokines, which can kill metastatic cancer. M2-TAMs secrete a variety of inhibitory cytokines, such as IL6, IL10, and TGFβ, and chemokines, such as CCL4, CCL5, and CCL22, to induce Tregs to migrate to the TME (Qian et al., 2011). However, macrophages are more likely to differentiate into the M2 phenotypes that promote tumor growth due to their own plasticity (Mantovani et al., 2017). Like MDSCs, M2-TAMs suppress the immune system around the tumor, induce tumor angiogenesis, and promote tumor progression.
5.1 Nanomaterials for inducing the polarization of macrophages from M2 to M1
TLR7 and TLR9 are expressed on the surface of macrophages but not on the surface of tumor cells (Trinchieri and Sher, 2007). TLR agonists induce TAMs to differentiate into the M1 phenotype and trigger the abscopal effect (Shan et al., 2020; Han et al., 2021). However, due to the poor pharmacokinetics of TLR agonists, even intratumoral administration cannot achieve the best results. Zhang et al. (2020) designed a thermosensitive liposome with TLR agonists, loaded them into phosphocholine liposomes. Compared with simple intratumoral injection, thermosensitive liposomes induced more M1-type TAMs, whereas there was almost no change in M2-TAMs. The application of thermosensitive liposomes obtained longer survival rates and better long-term immune memory (Zhang et al., 2020). However, the loading rate of the thermosensitive liposomes was not enough to trigger a powerful abscopal effect. Rodell et al. explored β-cyclodextrin nanoparticles (CDNPs) for carrying TLR agonists. CDNPs were able to aggregate within tumors and were specifically captured by macrophages 24 h after injection and could more strongly differentiate M2-TAMs from M1-TAMs (Rodell et al., 2018). Unlike the high macrophage affinity of β-cyclodextrin, apoptotic bodies (ABs) as a delivery vehicle has demonstrated a strong tumor accumulation potential. Encapsulation of ABs into nanoparticles is beneficial to increase nanoparticle deposition in tumor cells. Zheng et al. (2020a) conjugated CpG to gold-silver nanorods (AuNR) and loaded them into Abs (AuNR-CpG/AB). The loading efficiency of AuNR-CpG/ABs were 3.76% ± 0.55%. More than 80% of AuNR-CpG/ABs was deposited in miscellaneous tumor cells after intravenous injection in tumor-bearing mice.
Yook et al. explored Cetuximab-targeted gold nanorods (CTX-AuNR) (Emami et al., 2021). CTX-AuNR was about 11.2 ± 1.8 nm wide and 48.2 ± 2.5 nm long. The viability of BT-20 spheroids after photoimmunotherapy (PIT) of NT-AuNR near-infrared irradiation (NIR) was much higher than that of BT-20 spheroids grown with TAM (98.6% ± 0.6%). The addition of Bi(NO3)3 into nanoparticles acted as a photosensitizer (PT) and enhanced the abscopal effect of PTT-triggering immune effects (Emami et al., 2021). Bi-based nanomaterials loaded with doxorubicin and hyaluronic acid induced the conversion of TAMs from M2 to M1 (Emami et al., 2021). Hyaluronic acid nanoparticles loaded with MnO2 not only improved the local hypoxic state of the tumor but also induced the conversion of TAMs from M2 to M1 (Song et al., 2016; Parayath et al., 2018). In addition, macrophage colony-stimulating factors (M-CSFs) were key regulators of monocyte differentiation and formation and tissue-resident macrophage activity. Mao et al. used calcium carbonate as a cross-linking agent to load M-CSF into polyethylene glycol-polyglutamic acid nanoparticles (Mao et al., 2019). Nanoparticles have high drug loading efficiency (41.9% ± 12.4%). In vitro experiments showed that TAM can effectively accumulate within 1 h of injection. Nanoparticles reverse TAM phenotype and increase antitumor effect in tumor-bearing mice.
5.2 Nanomaterials for repolarizing macrophages into tumors
As a chemokine, chemokine (C-C motif) ligand 2 (CCL2)induces the migration of inflammatory cells and immune cells in the body. CCR2, as the receptor of CCL2, is mainly expressed in monocytes and NK cells (Hao et al., 2020). In addition, monocyte chemoattractant protein-1 (MCP-1) can also function through the CCR2 signaling pathway. CCR2 and its ligand Mcp1 pathway stimulate tumor cell proliferation (Ding et al., 2019). MCP1-CCR2 drives monocytes into the TME, which inhibits the anti-tumor activity of T cells. However, because Mcp1 inhibitors cannot be maintained in the body for a long time, the injection of Mcp1 inhibitors alone cannot cause sufficiently strong anti-tumor activity. Trac et al. (2020) explored the use of micelles to target CCR2 on monocytes and introduced apoptotic peptides into the micelles. These micelles were able to bind to monocytes in the body and induce their apoptosis, reduce the infiltration of TAMs into tumors, and promote the infiltration of T cells into the tumor, thereby enhancing the effect of immunotherapy. Shen et al. (2018) wrapped siCCR2 fragment (a siRNA for blocking CCR2 expression) in poly (ethylene glycol)-block-polylactide nanoparticles (PLG-PLA), which caused siCCR2 to target monocytes. SiCCR2 fragment-encapsulated polyethylene glycol-lactide nanoparticles. The diameter of cationic nanoparticles were 126.8 ± 15.6 nm. Cationic nanoparticles had better targeting of monocytes than neutral nanoparticles in breast cancer-bearing mice, and some of them blocked the expression of CCR2 on monocytes, blocked the infiltration of monocytes into tumor cells and reversed the immunosuppressive state in the TME. Moreover, cationic polymeric nanoparticles can promote tumors to produce CCL2 to recruit more immune cells, thereby enhancing the efficacy of chemotherapeutics (Leuschner et al., 2011; Liang et al., 2018b; Shen et al., 2018). However, these nanoparticles do not show that the abscopal effect can be enhanced.
Because of the unique biocompatibility of bismuth (Bi) and the ability of bismuth as PS to enhance PDT, Bi-based nanomaterials have been reported for bioapplications (Qin et al., 2020). Bi-based mesoporous upconversion nano-supported DOX. Lu explored a Bi-based mesoporous upconversion nanophosphor (UCNP) loaded with doxorubicin (UCNP-DOX) (Figure 3) (Qin et al., 2020). Bi(NO3)3 was dissolved in 20 ml of ethylene glycol and stirred until a clear solution formed. After adding DOX and stirring for 48 h, the solvent was evaporated. The diameter of UCNP-DOX was 85 nm. In vitro experiments show nanoparticles can be internalized by tumor cells and macrophages (Figure 3B). In the tumor-bearing mouse models of lung and colon cancer, after UCNP-DOX and X-ray treatment, the signal of CD68 (M1-TAM surface marker) in tumor tissue was strong, and the signal of CD206 (M2-TAM surface marker) was weak. The phenomenon showed that the level of M1 macrophages was increased, and the level of M2 macrophages was down-regulated (Figures 3C,D). The combination of nanoparticles and radiotherapy caused more M1-TAM than M2-TAM and delayed tumor growth (Figure 3E).
FIGURE 3. Mesoporous Bi-containing radiosensitizer to repolarize TAMs and boost abscopal effect. (A) The schematic of mesoporous Bi-containing radiosensitizer. (B) Confocal images of internalization of nanoparticles by lung cancer cells and macrophages. (C) After enhanced chemoradiotherapy of upconversion nanophosphor (UCNP) loaded with doxorubicin (UCNP-DOX) and X-ray, the tumor tissues showed intense CD68 and weak CD206 signals, showing the increased M1 macrophage level and down-regulated M2 macrophage level. (D) Polarization of macrophages in different treatment groups. (E) Fold change of tumor volume in all groups. Reproduced with permission from (Qin et al., 2020).
6 Nanomaterials for regulating cancer-associated fibroblast to trigger abscopal effect
In recent years, the role of cancer-associated fibroblast (CAF) in tumors has been recognized, and CAF has become a new target for cancer treatment. CAF inhibits tumor cell proliferation through TGF-β and IL-6 (Louault et al., 2020). However, CAF recruits inflammatory cells to reshape the extracellular matrix and promotes tumor blood vessel growth by secreting angiogenic factors (Erez et al., 2010). Furthermore, CAF promotes cancer cell invasion and metastasis through TGF-β and IL-32 and recruits MDSCs through CCL2, IL-1-β, monocytes, and so on to inhibit the anti-tumor effect of CD8+ T cells (Louault et al., 2020). Studies have confirmed that platelet-derived growth factor (PDGF) and TGFβ were the main factors for CAF activation (Micke and Ostman, 2005). Dasatinib treatment partially reversed the CAF phenotype in lung cancer tissues and reduce its ability to promote tumor proliferation in vitro (Haubeiss et al., 2010). Zhang et al. (2021) developed gold nanoparticles with a diameter of 20 nm that inhibited the expression of fibrin on the surface of CAF and thus inhibited the activation of CAF (Hossen et al., 2019). After gold nanoparticles were internalized by CAF, RT will caused more CAF damage (Bromma et al., 2020). In addition, PTT reshaped the tumor extracellular matrix and reduced the amount of CAF in the TME (Tan et al., 2019; Zheng et al., 2020b). The oxidized nanoparticles developed by Ferraz had the characteristics of fast and efficient cells internalization and low cytotoxicity (Ferraz et al., 2020). Ferric chloride and ferric sulfate were coprecipitated in sodium hydroxide solution and coated with trisodium citrate solution at 90°C for 30 min. Nanoparticles had an average diameter of 8.9 ± 2.4 nm in diameter. The oxidized nanoparticles were able to induce hyperthermia and human fibroblast cell death through apoptosis in vitro. They can induce heat generation and promote CAF apoptosis in a variable magnetic field. Although The oxidized nanoparticles promoted CAF apoptosis in vitro, it has not been verified in vivo.
Fibroblast activation protein (FAP) is important for CAF activation. Currently, FAP is the main target for CAF regulation (Lindner et al., 2019). Corsi et al. developed H-ferritin nanocages by utilizing metal ion affinity method; these were loaded with navitoclax and functionalized with FAP antibody fragments for targeting CAF (Figure 4A) (Sitia et al., 2021). HFn may contribute to increased Nav intratumoral accumulation due to HFn’s natural tumor homing and nanoparticle-mediated enhanced permeability and EPR effects. The poly ADP-ribose polymerase (PARP) cracking rate increased after treatment with H-ferritin nanocages (Figure 4B) (Chen et al., 2019). After encapsulation of FAP, H-ferritin nanocages exhibited high endocytosis efficiency (Figure 4C). FAP is highly expressed in CAF (Figure 4D). After the targeted elimination of CAF, it was observed that the growth of both the primary tumor and the distal tumor was delayed (Figures 4E,F). In addition, delivering oxygen to the TME is also a way to reverse the inhibitory TME. Duan et al. (2021) encapsulated perfluorocarbons (PFCs) with PLGA nanoparticles to improve peritumoral hypoxia levels. The PLGA nanoparticles were 110 nm in diameter. The addition of PFC can maintain the stability of nanoparticles. In addition, the addition of lignan-derived compounds to the nanoparticles was beneficial to promote the production of IL-25 by CAFs. IL-25 promoted tumor cell apoptosis. Regression of the primary tumor and metastases was observed 17 days after the nanoparticles were injected into the mice. However, whether PFC@PLGA reduces the number of CAFs has not been verified.
FIGURE 4. Engineered H-ferritin nanocage targets tumor-associated fibroblasts to induce anti-tumor immune response. (A) Development of H-Ferritin nanocages loaded with Navitoclax (Hnav) and HNav-fibroblast activation protein (FAP). (B) Calculated lysis of PARP-1 when CAF cells and breast cancer cells are incubated with 1 µM Nav or HNav. (C) Human activated myofibroblasts (HMFs) and breast cancer cellular uptake of Nav. (D) FAP expression in CAFs, HMfs, MDA-MB-231, and 4T1 cells. (E) The tumor growth curves in different treatment groups. (F) The survival rate in different treatment groups. Reproduced with permission from (Chen et al., 2019; Sitia et al., 2021).
7 Nanomaterials for regulating NK cells to trigger abscopal effect
NK cells are natural immune cells in the body, and they are the first line of defense against infection and tumors. Unlike T cells, NK cells do not need antigen stimulation to produce anti-tumor effects, nor do they need to secrete cytokines to regulate immune responses. NK cells secrete perforin and granzymes to induce cell death directly. Once tumor cells are recognized and attacked by NK cells, their efficiency is greatly reduced. However, NK cells alone cannot effectively eliminate tumors.
NK cells can target tumor cells through proteins such as receptor activators of nuclear factor-kappa B ligand (RANKL) or DNAX accessory molecule (DNAM-1) present in the NK cell membrane. Cai designed nanoparticles coated with NK cell membranes, which produced an abscopal effect to inhibit tumor growth (Figure 5) (Deng et al., 2018). Extracted NK cells membranes were extrusion-coated onto polymer nanoparticles loaded with PT. The nanoparticles were polymerized from mPEG-PLGA loaded with benzoic acid and had an average particle size of 80 ± 1.5 nm. In anti-tumor immunotherapy, NK cells induced the polarization of pro-inflammatory M1-macrophages and targeted tumor cells through proteins (such as RANKL or dNaM-1) present on the cell membranes of NK cells (Figure 5B). A schematic illustration of NK cells membrane-cloaked nanoparticles for PDT-enhanced cells membrane immunotherapy was shown in Figure 5A. NK cells membrane-cloaked nanoparticles increased the expression of the M1 macrophage’s markers iNOS and CD86 and decreased the expression of the M2 macrophage marker CD206 (Figure 5C). NK cells membrane-cloaked nanoparticles also increased the production of M1 macrophage-related cytokines (TNF-α, IL-6, and IL-12). NK-NPs were able to eliminate primary tumor growth and produce the abscopal effect to inhibit the growth of distant tumors (Figures 5D,E). NK cells membrane-cloaked nanoparticles also improved the survival time of experimental mice (Figure 5F). Although NK cells have a strong killing function, they need to activate the immune system to kill tumors.
FIGURE 5. Immunotherapy based on NK cell membrane coated nanoparticles for the effective inhibition of abscopal tumor growth. (A) Schematic illustration of NK cell-membrane-cloaked nanoparticles for PDT-enhanced cell-membrane immunotherapy. (B) Human NK-NPs and pro-inflammatory M1-macrophage polarization in THP-1 cells. (C) The signs of M1-macrophage activation in vitro. (D) The tumor volume of primary tumor. (E) The tumor volume of distant tumor. (F) The survival rate of all groups. Reproduced with permission from (Deng et al., 2018).
8 Conclusion and perspectives
Cancer metastasis is the leading cause of death in cancer patients, as there are no effective clinical treatments for metastatic cancer. In recent years, abscopal effects associated with immunotherapy have been observed. However, immunotherapy has only been effective in triggering the abscopal effect in basic experiments. Moreover, immunotherapy can cause harm to the body by introducing excessive inflammatory factors and cytokines. Therefore, nanomaterial-based delivery methods for immunotherapeutic agents have been developed. With the continued development of nanomaterials, the immune-induced abscopal effect may become more feasible for the treatment of metastatic tumors. Immune cells play a key role in killing metastatic cancer cells. Nanomaterials can be designed to induce tumor antigen exposure, lead to DC and T cell maturation, suppress immunosuppressive cells, increase the number of T cells around metastases, and in general reverse the immunosuppressive microenvironment to provide favorable conditions for the removal of metastases. In preclinical studies, nanomaterials have been proven to enhance the abscopal effect and reduce the negative effects (e.g., immune off-target and irAEs) of immunotherapy. Nanomaterials also offer a promising pathway for the combination of immunotherapy and other treatment methods such as RT and chemotherapy.
However, TAM is a complex system. How to design nanomaterials that target tumor cells is important. At present, acid-responsive, hypoxia-responsive, and metal-responsive nanomaterials have been reported by many researchers. These nanomaterials achieved good results in mice. Although the specific mechanism of the abscopal effect is still unclear, the abscopal effect of nanomaterials triggered by immunotherapy has also been confirmed in animal experiments. However, abscopal effects are not found in all metastases. This phenomenon is still observed in only a minority of tumors. Although we have made breakthroughs in studying primary tumors with different nanomaterials, the study of metastases still needs to be explored further.
Author contributions
All authors read and approved the final manuscript. YL wrote the initial manuscript. CF and YL contributed new ideas. RY and HW created the figures. RY and YX created Table 1. YL, RY, JZ, JF, and HW revised the manuscript and approved the final version.
Funding
This work was supported by the National Natural Science Foundation of China (Grant Nos. 82071391), the Science and Technology Development Program of Jilin Province (Grant No. 20200404182YY), the Provincial Health Special Project of Jilin Province (Grant No. JLSWSRCZX2020-104), the “13th Five-Year” Science and Technology Research Planning Project of Jilin Province (Grant No. JLKHJJKH20190042KJ), and the Achievement Transformation Fund of the First Hospital of Jilin University (Grant No. JDYYZH-2102052).
Acknowledgments
We would like to express our appreciation to everyone involved in drafting and preparing the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Alvisi, G., Brummelman, J., Puccio, S., Mazza, E. M., Tomada, E. P., Losurdo, A., et al. (2020). IRF4 instructs effector Treg differentiation and immune suppression in human cancer. J. Clin. Invest. 130 (6), 3137–3150. doi:10.1172/jci130426
Atrafi, F., van Eerden, R. A. G., van Hylckama Vlieg, M. A. M., Oomen-de Hoop, E., de Bruijn, P., Lolkema, M. P., et al. (2020). Intratumoral comparison of nanoparticle entrapped docetaxel (CPC634) with conventional docetaxel in patients with solid tumors. Clin. Cancer Res. 26 (14), 3537–3545. doi:10.1158/1078-0432.ccr-20-0008
Barberio, A. E., Smith, S. G., Correa, S., Nguyen, C., Nhan, B., Melo, M., et al. (2020). Cancer cell coating nanoparticles for optimal tumor-specific cytokine delivery. ACS Nano 14 (9), 11238–11253. doi:10.1021/acsnano.0c03109
Bromma, K., Cicon, L., Beckham, W., and Chithrani, D. B. (2020). Gold nanoparticle mediated radiation response among key cell components of the tumour microenvironment for the advancement of cancer nanotechnology. Sci. Rep. 10 (1), 12096–96. doi:10.1038/s41598-020-68994-0
Brown, R. D., Pope, B., Murray, A., Esdale, W., Sze, D. M., Gibson, J., et al. (2001). Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10. Blood 98 (10), 2992–2998. doi:10.1182/blood.v98.10.2992
Buss, C. G., and Bhatia, S. N. (2020). Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics. Proc. Natl. Acad. Sci. U. S. A. 117 (24), 13428–13436. doi:10.1073/pnas.2001569117
Cable, J., Greenbaum, B., Pe’er, D., Bollard, C. M., Bruni, S., Griffin, M. E., et al. (2021). Frontiers in cancer immunotherapy-a symposium report. Ann. N. Y. Acad. Sci. 1489 (1), 30–47. doi:10.1111/nyas.14526
Cano-Mejia, J., Shukla, A., Ledezma, D. K., Palmer, E., Villagra, A., and Fernandes, R. (2020). CpG-coated prussian blue nanoparticles-based photothermal therapy combined with anti-CTLA-4 immune checkpoint blockade triggers a robust abscopal effect against neuroblastoma. Transl. Oncol. 13 (10), 100823–23. doi:10.1016/j.tranon.2020.100823
Cao, Q., Wang, W., Zhou, M., Huang, Q., Wen, X., Zhao, J., et al. (2020). Induction of anti-tumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition. Nanomedicine Nanotechnol. Biol. Med. 25, 102169. doi:10.1016/j.nano.2020.102169
Chen, M., Quan, G., Wen, T., Yang, P., Qin, W., Mai, H., et al. (2020). Cold to hot: Binary cooperative microneedle array-amplified photoimmunotherapy for eliciting antitumor immunity and the abscopal effect. ACS Appl. Mat. Interfaces 12 (29), 32259–32269. doi:10.1021/acsami.0c05090
Chen, M., Xu, G., Fan, M., Jia, H., Xiao, L., and Lang, J. (2019). Anti-tumour effects of a xenogeneic fibroblast activation protein-based whole cell tumour vaccine in murine tumour models. Artif. Cells Nanomed. Biotechnol. 47 (1), 4182–4193. doi:10.1080/21691401.2019.1687498
Chen, Z., Liu, L., Liang, R., Luo, Z., He, H., Wu, Z., et al. (2018). Bioinspired hybrid protein oxygen nanocarrier amplified photodynamic therapy for eliciting anti-tumor immunity and abscopal effect. ACS Nano 12 (8), 8633–8645. doi:10.1021/acsnano.8b04371
Darling, R., Senapati, S., Christiansen, J., Liu, L., Ramer-Tait, A. E., Narasimhan, B., et al. (2020). Polyanhydride nanoparticles induce low inflammatory dendritic cell activation resulting in CD8+ T cell memory and delayed tumor progression. Int. J. Nanomedicine 15, 6579–6592. doi:10.2147/ijn.s261041
De Cicco, P., Ercolano, G., and Ianaro, A. (2020). The new era of cancer immunotherapy: Targeting myeloid-derived suppressor cells to overcome immune evasion. Front. Immunol. 11, 1680. doi:10.3389/fimmu.2020.01680
Deng, G., Sun, Z., Li, S., Peng, X., Li, W., Zhou, L., et al. (2018). Cell-membrane immunotherapy based on natural killer cell membrane coated nanoparticles for the effective inhibition of primary and abscopal tumor growth. ACS Nano 12 (12), 12096–12108. doi:10.1021/acsnano.8b05292
Deng, L., Pan, X., Zhang, Y., Sun, S., Lv, L., Gao, L., et al. (2020). Immunostimulatory potential of MoS(2) nanosheets: enhancing dendritic cell maturation, migration and T cell elicitation. Int. J. Nanomedicine 15, 2971–2986. doi:10.2147/ijn.s243537
DeOca, K. B., Moorman, C. D., Garcia, B. L., and Mannie, M. D. (2020). Low-zone IL-2 signaling: Fusion proteins containing linked CD25 and IL-2 domains sustain tolerogenic vaccination in vivo and promote dominance of FOXP3(+) Tregs in vitro. Front. Immunol. 11, 541619–19. doi:10.3389/fimmu.2020.541619
Desai, R., Coxon, A. T., and Dunn, G. P. (2022). Therapeutic applications of the cancer immunoediting hypothesis. Semin. Cancer Biol. 78, 63–77. doi:10.1016/j.semcancer.2021.03.002
Dill, E. A., Dillon, P. M., Bullock, T. N., and Mills, A. M. (2018). Ido expression in breast cancer: An assessment of 281 primary and metastatic cases with comparison to PD-L1. Mod. Pathol. 31 (10), 1513–1522. doi:10.1038/s41379-018-0061-3
Ding, M., He, S. J., and Yang, J. (2019). MCP-1/CCL2 mediated by autocrine loop of PDGF-BB promotes invasion of lung cancer cell by recruitment of macrophages via CCL2-CCR2 Axis. J. Interferon Cytokine Res. 39 (4), 224–232. doi:10.1089/jir.2018.0113
Du, B., Du, Q., Bai, Y., Yu, L., Wang, Y., Huang, J., et al. (2020). Chemotherapy based on “Domino-effect” combined with immunotherapy amplifying the efficacy of an antimetastatic treatment. J. Mat. Chem. B 8, 9139–9150. doi:10.1039/d0tb01061h
Duan, Z., Luo, Q., Gu, L., Li, X., Zhu, H., Gu, Z., et al. (2021). A co-delivery nanoplatform for a lignan-derived compound and perfluorocarbon tuning IL-25 secretion and the oxygen level in tumor microenvironments for meliorative tumor radiotherapy. Nanoscale 13 (32), 13681–13692. doi:10.1039/d1nr03738b
Dudek, A. M., Martin, S., Garg, A. D., and Agostinis, P. (2013). Immature, semi-mature, and fully mature dendritic cells: Toward a DC-cancer cells interface that augments anticancer immunity. Front. Immunol. 4, 438. doi:10.3389/fimmu.2013.00438
Eckert, F., Schilbach, K., Klumpp, L., Bardoscia, L., Sezgin, E. C., Schwab, M., et al. (2018). Potential role of CXCR4 targeting in the context of radiotherapy and immunotherapy of cancer. Front. Immunol. 9, 3018. doi:10.3389/fimmu.2018.03018
Emami, F., Pathak, S., Nguyen, T. T., Shrestha, P., Maharjan, S., Kim, J. O., et al. (2021). Photoimmunotherapy with cetuximab-conjugated gold nanorods reduces drug resistance in triple negative breast cancer spheroids with enhanced infiltration of tumor-associated macrophages. J. Control. Release 329, 645–664. doi:10.1016/j.jconrel.2020.10.001
Erez, N., Truitt, M., Olson, P., Arron, S. T., and Hanahan, D. (2010). Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-Dependent manner. Cancer Cell 17 (2), 135–147. doi:10.1016/j.ccr.2009.12.041
Fenton, O. S., Tibbitt, M. W., Appel, E. A., Jhunjhunwala, S., Webber, M. J., and Langer, R. (2019). Injectable polymer-nanoparticle hydrogels for local immune cell recruitment. Biomacromolecules 20 (12), 4430–4436. doi:10.1021/acs.biomac.9b01129
Ferraz, F. S., López, J. L., Lacerda, S., Procopio, M. S., Figueiredo, A. F., Martins, E. M., et al. (2020). Biotechnological approach to induce human fibroblast apoptosis using superparamagnetic iron oxide nanoparticles. J. Inorg. Biochem. 206, 111017. doi:10.1016/j.jinorgbio.2020.111017
Fu, Z., and Xiang, J. (2020). Aptamer-functionalized nanoparticles in targeted delivery and cancer therapy. Int. J. Mol. Sci. 21 (23), 9123. doi:10.3390/ijms21239123
Ganesh, K., and Massagué, J. (2021). Targeting metastatic cancer. Nat. Med. 27 (1), 34–44. doi:10.1038/s41591-020-01195-4
Gardner, A., de Mingo Pulido, Á., and Ruffell, B. (2020). Dendritic cells and their role in immunotherapy. Front. Immunol. 11, 924. doi:10.3389/fimmu.2020.00924
Goldszmid, R. S., Dzutsev, A., and Trinchieri, G. (2014). Host immune response to infection and cancer: Unexpected commonalities. Cell Host Microbe 15 (3), 295–305. doi:10.1016/j.chom.2014.02.003
Gomes, E. R., and Franco, M. S. (2022). Combining nanocarrier-assisted delivery of molecules and radiotherapy. Pharmaceutics 14 (8), 105. doi:10.3390/pharmaceutics14010105
Grzywa, T. M., Sosnowska, A., Matryba, P., Rydzynska, Z., Jasinski, M., Nowis, D., et al. (2020). Myeloid cell-derived arginase in cancer immune response. Front. Immunol. 11, 938. doi:10.3389/fimmu.2020.00938
Gu, Z., Da Silva, C. G., Van der Maaden, K., Ossendorp, F., and Cruz, L. J. (2020). Liposome-based drug delivery systems in cancer immunotherapy. Pharmaceutics 12 (11), 1054. doi:10.3390/pharmaceutics12111054
Han, S., Wang, W., Wang, S., Yang, T., Zhang, G., Wang, D., et al. (2021). Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes. Theranostics 11 (6), 2892–2916. doi:10.7150/thno.50928
Han, Y., Liu, D., and Li, L. (2020). PD-1/PD-L1 pathway: Current researches in cancer. Am. J. Cancer Res. 10 (3), 727–742.
Hao, Q., Vadgama, J. V., and Wang, P. (2020). CCL2/CCR2 signaling in cancer pathogenesis. Cell Commun. Signal. 18 (1), 82. doi:10.1186/s12964-020-00589-8
Haubeiss, S., Schmid, J. O., Mürdter, T. E., Sonnenberg, M., Friedel, G., van der Kuip, H., et al. (2010). Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol. Cancer 9, 168–68. doi:10.1186/1476-4598-9-168
Heidari, F., Ramezani, A., Erfani, N., and Razmkhah, M. (2020). Indoleamine 2, 3-dioxygenase: A professional immunomodulator and its potential functions in immune related diseases. Int. Rev. Immunol. 41, 346–363. doi:10.1080/08830185.2020.1836176
Hommes, J. W., Verheijden, R. J., and SuijkerbuijkHamann, K. P. M. D. (2021). Biomarkers of checkpoint inhibitor induced immune-related adverse events-A comprehensive review. Front. Oncol. 10, 585311. doi:10.3389/fonc.2020.585311
Horwitz, D. A., Bickerton, S., Koss, M., Fahmy, T. M., and La Cava, A. (2019). Suppression of murine lupus by CD4+ and CD8+ treg cells induced by T cell-targeted nanoparticles loaded with interleukin-2 and transforming growth factor β. Arthritis Rheumatol. 71 (4), 632–640. doi:10.1002/art.40773
Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., and Baradaran, B. (2020). CTLA-4: From mechanism to autoimmune therapy. Int. Immunopharmacol. 80, 106221. doi:10.1016/j.intimp.2020.106221
Hossen, M. N., Rao, G., Dey, A., Robertson, J. D., Bhattacharya, R., and Mukherjee, P. (2019). Gold nanoparticle transforms activated cancer-associated fibroblasts to quiescence. ACS Appl. Mat. Interfaces 11 (29), 26060–26068. doi:10.1021/acsami.9b03313
Hu, L., Cao, Z., Ma, L., Liu, Z., Liao, G., Wang, J., et al. (2019). The potentiated checkpoint blockade immunotherapy by ROS-responsive nanocarrier-mediated cascade chemo-photodynamic therapy. Biomaterials 223, 119469. doi:10.1016/j.biomaterials.2019.119469
Hu, X., Deng, Q., Ma, L., Li, Q., Chen, Y., Liao, Y., et al. (2020). Meningeal lymphatic vessels regulate brain tumor drainage and immunity. Cell Res. 30 (3), 229–243. doi:10.1038/s41422-020-0287-8
Huang, J., Xiao, Z., An, Y., Han, S., Wu, W., Wang, Y., et al. (2021). Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anticancer therapy. Biomaterials 269, 120636. doi:10.1016/j.biomaterials.2020.120636
Hwang, H. S., Cherukula, K., Bang, Y. J., Vijayan, V., Moon, M. J., Thiruppathi, J., et al. (2020). Combination of photodynamic therapy and a flagellin-adjuvanted cancer vaccine potentiated the anti-PD-1-mediated melanoma suppression. Cells 9 (11), 2432. doi:10.3390/cells9112432
Ishiyama, Y., Takagi, T., Yoshida, K., Iizuka, J., Kakuta, Y., Okumi, M., et al. (2019). Possible abscopal effect in urothelial carcinoma of the upper urinary tract after treatment with immune checkpoint inhibitors. IJU Case Rep. 3 (1), 25–27. doi:10.1002/iju5.12133
Kohno, M., Murakami, J., Wu, L., Chan, M. L., Yun, Z., Cho, B. C. J., et al. (2020). Foxp3(+) regulatory T cell depletion after nonablative oligofractionated irradiation boosts the abscopal effects in murine malignant mesothelioma. J. I. 205 (9), 2519–2531. doi:10.4049/jimmunol.2000487
Kong, Y. Y., Wilson, K., Apostolopoulos, V., and Plebanski, M. (2020). Dendritic cells and myeloid derived suppressor cells fully responsive to stimulation via toll-like receptor 4 are rapidly induced from bone-marrow cells by granulocyte-macrophage colony-stimulating factor. Vaccines 8 (3), 522. doi:10.3390/vaccines8030522
Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., et al. (2005). Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent anti-tumor immunity. Nat. Med. 11 (12), 1314–1321. doi:10.1038/nm1325
Krieg, A. M. (2007). Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 117 (5), 1184–1194. doi:10.1172/jci31414
Kuang, J., Song, W., Yin, J., Zeng, X., Han, S., Zhao, Y. P., et al. (2018). iRGD modified chemo-immunotherapeutic nanoparticles for enhanced immunotherapy against glioblastoma. Adv. Funct. Mat. 28 (17), 1800025. doi:10.1002/adfm.201800025
Kumar, V., Cheng, P., Condamine, T., Mony, S., Languino, L. R., McCaffrey, J. C., et al. (2016). CD45 phosphatase inhibits STAT3 transcription factor Activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity 44 (2), 303–315. doi:10.1016/j.immuni.2016.01.014
Kumar, V., Patel, S., Tcyganov, E., and Gabrilovich, D. I. (2016). The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37 (3), 208–220. doi:10.1016/j.it.2016.01.004
Kusmartsev, S., Cheng, F., Yu, B., Nefedova, Y., Sotomayor, E., Lush, R., et al. (2003). All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63 (15), 4441–4449.
Kusmartsev, S., and Gabrilovich, D. I. (2003). Inhibition of myeloid cell differentiation in cancer: The role of reactive oxygen species. J. Leukoc. Biol. 74 (2), 186–196. doi:10.1189/jlb.0103010
Lau, S. P., van Montfoort, N., Kinderman, P., Lukkes, M., Klaase, L., van Nimwegen, M., et al. (2020). Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent anti-tumor immunity in a pancreatic carcinoma murine model. J. Immunother. Cancer 8 (2), e000772. doi:10.1136/jitc-2020-000772
Law, A. M. K., Valdes-Mora, F., and Gallego-Ortega, D. (2020). Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells 9 (3), 561. doi:10.3390/cells9030561
Legoux, F. P., Lim, J. B., Cauley, A. W., Dikiy, S., Ertelt, J., Mariani, T., et al. (2015). CD4+ T cell tolerance to tissue-restricted self antigens is mediated by antigen-specific regulatory T cells rather than deletion. Immunity 43 (5), 896–908. doi:10.1016/j.immuni.2015.10.011
Leong, W. I., Ames, R. Y., Haverkamp, J. M., Torres, L., Kline, J., Bans, A., et al. (2019). Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses. Oncotarget 10 (68), 7220–7237. doi:10.18632/oncotarget.27322
Leuschner, F., Dutta, P., Gorbatov, R., Novobrantseva, T. I., Donahoe, J. S., Courties, G., et al. (2011). Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 29 (11), 1005–1010. doi:10.1038/nbt.1989
Li, Q., Liu, J., Fan, H., Shi, L., Deng, Y., Zhao, L., et al. (2020). Ido-inhibitor potentiated immunogenic chemotherapy abolishes primary tumor growth and eradicates metastatic lesions by targeting distinct compartments within tumor microenvironment. Biomaterials 269, 120388. doi:10.1016/j.biomaterials.2020.120388
Li, W., Peng, A., Wu, H., Quan, Y., Li, Y., Lu, L., et al. (2020). Anti-cancer nanomedicines: A revolution of tumor immunotherapy. Front. Immunol. 11, 601497–97. doi:10.3389/fimmu.2020.601497
Liang, R., Liu, L., He, H., Chen, Z., Han, Z., Luo, Z., et al. (2018). Oxygen-boosted immunogenic photodynamic therapy with gold nanocages@manganese dioxide to inhibit tumor growth and metastases. Biomaterials 177, 149–160. doi:10.1016/j.biomaterials.2018.05.051
Liang, S., Zheng, J., Wu, W., Li, Q., Saw, P. E., Chen, J., et al. (2018). A robust nanoparticle platform for RNA interference in macrophages to suppress tumor cell migration. Front. Pharmacol. 9, 1465. doi:10.3389/fphar.2018.01465
Lin, X., Wang, X., Li, J., Cai, L., Liao, F., Wu, M., et al. (2021). Localized NIR-II photo-immunotherapy through the combination of photothermal ablation and in situ generated interleukin-12 cytokine for efficiently eliminating primary and abscopal tumors. Nanoscale 13 (3), 1745–1758. doi:10.1039/d0nr06182d
Lindner, T., Loktev, A., Giesel, F., Kratochwil, C., Altmann, A., and Haberkorn, U. (2019). Targeting of activated fibroblasts for imaging and therapy. EJNMMI Radiopharm. Chem. 4 (1), 16. doi:10.1186/s41181-019-0069-0
Liu, D., Chen, B., Mo, Y., Wang, Z., Qi, T., Zhang, Q., et al. (2019). Redox-activated porphyrin-based liposome remote-loaded with indoleamine 2, 3-dioxygenase (Ido) inhibitor for synergistic photoimmunotherapy through induction of immunogenic cell death and blockage of Ido pathway. Nano Lett. 19 (10), 6964–6976. doi:10.1021/acs.nanolett.9b02306
Liu, H-C., Viswanath, D. I., Pesaresi, F., Xu, Y., Zhang, L., Di Trani, N., et al. (2020). Potentiating anti-tumor efficacy through radiation and sustained intratumoral delivery of anti-CD40 and anti-PDL1. Int. J. Radiat. Oncology*Biology*Physics 1110 (2), 492–506. doi:10.1016/j.ijrobp.2020.07.2326
Liu, Y., Liang, X., Yin, X., Lv, J., Tang, K., Ma, J., et al. (2017). Blockade of Ido-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells. Nat. Commun. 8, 15207–07. doi:10.1038/ncomms15207
Liu, Y., Zhou, N., Zhou, L., Wang, J., Zhang, T., Zhou, Y., et al. (2021). IL-2 regulates tumor-reactive CD8(+) T cell exhaustion by activating the aryl hydrocarbon receptor. Nat. Immunol. 22 (3), 358–369. doi:10.1038/s41590-020-00850-9
Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., et al. (2016). Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol. Res. 4 (10), 869–880. doi:10.1158/2326-6066.cir-15-0230
Long, Y., Lu, Z., Xu, S., Li, M., Wang, X., Zhang, Z., et al. (2020). Self-delivery micellar nanoparticles prevent premetastatic niche formation by interfering with the early recruitment and vascular destruction of granulocytic myeloid-derived suppressor cells. Nano Lett. 20 (4), 2219–2229. doi:10.1021/acs.nanolett.9b03883
Louault, K., Li, R. R., and DeClerck, Y. A. (2020). Cancer-associated fibroblasts: Understanding their heterogeneity. Cancers (Basel) 12 (11), 3108. doi:10.3390/cancers12113108
Lu, Z., Long, Y., Wang, Y., Wang, X., Xia, C., Li, M., et al. (2021). Phenylboronic acid modified nanoparticles simultaneously target pancreatic cancer and its metastasis and alleviate immunosuppression. Eur. J. Pharm. Biopharm. 165, 164–173. doi:10.1016/j.ejpb.2021.05.014
Lui, P. P., Cho, I., and Ali, N. (2020). Tissue regulatory T cells. Immunology 161 (1), 4–17. doi:10.1111/imm.13208
Luo, Z., He, T., Liu, P., Yi, Z., Zhu, S., Liang, X., et al. (2021). Self-adjuvanted molecular activator (SeaMac) nanovaccines promote cancer immunotherapy. Adv. Healthc. Mat. 10 (7), e2002080. doi:10.1002/adhm.202002080
Mantovani, A., and Locati, M. (2013). Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: Lessons and open questions. Arterioscler. Thromb. Vasc. Biol. 33 (7), 1478–1483. doi:10.1161/atvbaha.113.300168
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., and Allavena, P. (2017). Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14 (7), 399–416. doi:10.1038/nrclinonc.2016.217
Mao, K., Cong, X., Feng, L., Chen, H., Wang, J., Wu, C., et al. (2019). Intratumoral delivery of M-CSF by calcium crosslinked polymer micelles enhances cancer immunotherapy. Biomater. Sci. 7 (7), 2769–2776. doi:10.1039/c9bm00226j
McCaw, T. R., Li, M., Starenki, D., Liu, M., Cooper, S. J., Arend, R. C., et al. (2019). Histone deacetylase inhibition promotes intratumoral CD8(+) T-cell responses, sensitizing murine breast tumors to anti-PD1. Cancer Immunol. Immunother. 68 (12), 2081–2094. doi:10.1007/s00262-019-02430-9
McHugh, M. D., Park, J., Uhrich, R., Gao, W., Horwitz, D. A., and Fahmy, T. M. (2015). Paracrine co-delivery of TGF-β and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells. Biomaterials 59, 172–181. doi:10.1016/j.biomaterials.2015.04.003
Meireson, A., Devos, M., and Brochez, L. (2020). Ido expression in cancer: Different compartment, different functionality? Front. Immunol. 11, 531491. doi:10.3389/fimmu.2020.531491
Micke, P., and Ostman, A. (2005). Exploring the tumour environment: Cancer-associated fibroblasts as targets in cancer therapy. Expert Opin. Ther. Targets 9 (6), 1217–1233. doi:10.1517/14728222.9.6.1217
Min, Y., Roche, K. C., Tian, S., Eblan, M. J., McKinnon, K. P., Caster, J. M., et al. (2017). Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat. Nanotechnol. 12 (9), 877–882. doi:10.1038/nnano.2017.113
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., and Langer, R. (2021). Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20 (2), 101–124. doi:10.1038/s41573-020-0090-8
Morales-Orue, I., Chicas-Sett, R., and Lara, P. C. (2019). Nanoparticles as a promising method to enhance the abscopal effect in the era of new targeted therapies. Rep. Pract. Oncol. Radiother. 24 (1), 86–91. doi:10.1016/j.rpor.2018.11.001
Nasirmoghadas, P., Mousakhani, A., Behzad, F., Beheshtkhoo, N., Hassanzadeh, A., Nikoo, M., et al. (2021). Nanoparticles in cancer immunotherapies: An innovative strategy. Biotechnol. Prog. 37 (2), e3070. doi:10.1002/btpr.3070
Nefedova, Y., Fishman, M., Sherman, S., Wang, X., Beg, A. A., and Gabrilovich, D. I. (2007). Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 67 (22), 11021–11028. doi:10.1158/0008-5472.can-07-2593
Nguyen, K. G., Vrabel, M. R., Mantooth, S. M., Hopkins, J. J., Wagner, E. S., Gabaldon, T. A., et al. (2020). Localized interleukin-12 for cancer immunotherapy. Front. Immunol. 11, 575597–97. doi:10.3389/fimmu.2020.575597
Nguyen, T. L., Cha, B. G., Choi, Y., Im, J., and Kim, J. (2020). Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold. Biomaterials 239, 119859. doi:10.1016/j.biomaterials.2020.119859
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., and Formenti, S. C. (2018). Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18 (5), 313–322. doi:10.1038/nrc.2018.6
Ni, K., Lan, G., Chan, C., Duan, X., Guo, N., Veroneau, S. S., et al. (2019). Ultrathin metal-organic-layer mediated radiotherapy-radiodynamic therapy. Matter 1 (5), 1331–1353. doi:10.1016/j.matt.2019.06.007
Ni, K., Luo, T., Lan, G., Culbert, A., Song, Y., Wu, T., et al. (2020). A nanoscale metal-organic framework to mediate photodynamic therapy and deliver CpG oligodeoxynucleotides to enhance antigen presentation and cancer immunotherapy. Angew. Chem. Intl. Ed. 59 (3), 1108–1112. doi:10.1002/anie.201911429
Nicholas, D., Nesbitt, H., Farrell, S., Logan, K., McMullin, E., Gillan, T., et al. (2021). Exploiting a Rose Bengal-bearing, oxygen-producing nanoparticle for SDT and associated immune-mediated therapeutic effects in the treatment of pancreatic cancer. Eur. J. Pharm. Biopharm. 163, 49–59. doi:10.1016/j.ejpb.2021.03.005
Pagani, O., Senkus, E., Wood, W., Colleoni, M., Cufer, T., Kyriakides, S., et al. (2010). International guidelines for management of metastatic breast cancer: Can metastatic breast cancer be cured? JNCI J. Natl. Cancer Inst. 102 (7), 456–463. doi:10.1093/jnci/djq029
Pang, G., Chen, C., Liu, Y., Jiang, T., Yu, H., Wu, Y., et al. (2019). Bioactive polysaccharide nanoparticles improve radiation-induced abscopal effect through manipulation of dendritic cells. ACS Appl. Mat. Interfaces 11 (45), 42661–42670. doi:10.1021/acsami.9b16814
Parayath, N. N., Parikh, A., and Amiji, M. M. (2018). Repolarization of tumor-associated macrophages in a genetically engineered nonsmall cell lung cancer model by intraperitoneal administration of hyaluronic acid-based nanoparticles encapsulating MicroRNA-125b. Nano Lett. 18 (6), 3571–3579. doi:10.1021/acs.nanolett.8b00689
Park, J., Wrzesinski, S. H., Stern, E., Look, M., Criscione, J., Ragheb, R., et al. (2012). Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat. Mat. 11 (10), 895–905. doi:10.1038/nmat3355
Perry, J. L., Tian, S., Sengottuvel, N., Harrison, E. B., Gorentla, B. K., Kapadia, C. H., et al. (2020). Pulmonary delivery of nanoparticle-bound toll-like receptor 9 agonist for the treatment of metastatic lung cancer. ACS Nano 14 (6), 7200–7215. doi:10.1021/acsnano.0c02207
Poelaert, B. J., Romanova, S., Knoche, S. M., Olson, M. T., Sliker, B. H., Smits, K., et al. (2020). Nanoformulation of CCL21 greatly increases its effectiveness as an immunotherapy for neuroblastoma. J. Control. Release 327, 266–283. doi:10.1016/j.jconrel.2020.07.024
Prendergast, G. C., Malachowski, W. J., Mondal, A., Scherle, P., and Muller, A. J. (2018). Indoleamine 2, 3-dioxygenase and its therapeutic inhibition in cancer. Int. Rev. Cell Mol. Biol. 336, 175–203. doi:10.1016/bs.ircmb.2017.07.004
Qian, B-Z., Li, J., Zhang, H., Kitamura, T., Campion, L. R., Zhang, J., et al. (2011). CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475 (7355), 222–225. doi:10.1038/nature10138
Qin, X., Liu, J., Xu, Y., Li, B., Cheng, J., Wu, X., et al. (2020). Mesoporous Bi-containing radiosensitizer loading with DOX to repolarize tumor-associated macrophages and elicit immunogenic tumor cell death to inhibit tumor progression. ACS Appl. Mat. Interfaces 12 (28), 31225–31234. doi:10.1021/acsami.0c08074
Qiu, N., Liu, Y., Liu, Q., Chen, Y., Shen, L., Hu, M., et al. (2021). Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy. Biomaterials 269, 120604. doi:10.1016/j.biomaterials.2020.120604
Raffin, C., Vo, L. T., and Bluestone, J. A. (2020). T(reg) cell-based therapies: Challenges and perspectives. Nat. Rev. Immunol. 20 (3), 158–172. doi:10.1038/s41577-019-0232-6
Raker, V. K., Becker, C., Landfester, K., and Steinbrink, K. (2020). Targeted activation of T cells with IL-2-coupled nanoparticles. Cells 9 (9), 2063. doi:10.3390/cells9092063
Ren, B., Luo, S., Tian, X., Jiang, Z., Zou, G., Xu, F., et al. (2018). Curcumin inhibits liver cancer by inhibiting DAMP molecule HSP70 and TLR4 signaling. Oncol. Rep. 40 (2), 895–901. doi:10.3892/or.2018.6485
Robertson, M. J., Cameron, C., Atkins, M. B., Gordon, M. S., Lotze, M. T., Sherman, M. L., et al. (1999). Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin. Cancer Res. 5 (1), 9–16.
Rodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., et al. (2018). TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat. Biomed. Eng. 2 (8), 578–588. doi:10.1038/s41551-018-0236-8
Röhrle, N., Knott, M. M. L., and Anz, D. (2020). CCL22 signaling in the tumor environment. Adv. Exp. Med. Biol. 1231, 79–96. doi:10.1007/978-3-030-36667-4_8
Roth, F., De La Fuente, A. C., Vella, J. L., Zoso, A., Inverardi, L., and Serafini, P. (2012). Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression. Cancer Res. 72 (6), 1373–1383. doi:10.1158/0008-5472.can-11-2772
Saadeldin, M. K., Abdel-Aziz, A. K., and Abdellatif, A. (2021). Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis. Med. Hypotheses 146, 110365–65. doi:10.1016/j.mehy.2020.110365
Sacchi, A., Tumino, N., Sabatini, A., Cimini, E., Casetti, R., Bordoni, V., et al. (2018). Myeloid-derived suppressor cells specifically suppress IFN-γ production and antitumor cytotoxic activity of vδ2 T cells. Front. Immunol. 9, 1271. doi:10.3389/fimmu.2018.01271
Schmidt, A., Oberle, N., and Krammer, P. H. (2012). Molecular mechanisms of treg-mediated T cell suppression. Front. Immunol. 3, 51. doi:10.3389/fimmu.2012.00051
Shan, H., Dou, W., Zhang, Y., and Qi, M. (2020). Targeted ferritin nanoparticle encapsulating CpG oligodeoxynucleotides induces tumor-associated macrophage M2 phenotype polarization into M1 phenotype and inhibits tumor growth. Nanoscale 12 (43), 22268–22280. doi:10.1039/d0nr04520a
Sharma, M., Khong, H., Fa’ak, F., Bentebibel, S. E., Janssen, L. M. E., Chesson, B. C., et al. (2020). Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat. Commun. 11 (1), 661–61. doi:10.1038/s41467-020-14471-1
Shen, S., Zhang, Y., Chen, K. G., Luo, Y. L., and Wang, J. (2018). Cationic polymeric nanoparticle delivering CCR2 siRNA to inflammatory monocytes for tumor microenvironment modification and cancer therapy. Mol. Pharm. 15 (9), 3642–3653. doi:10.1021/acs.molpharmaceut.7b00997
Shi, H., Lan, J., and Yang, J. (2020). Mechanisms of resistance to checkpoint blockade therapy. Adv. Exp. Med. Biol. 1248, 83–117. doi:10.1007/978-981-15-3266-5_5
Shirota, Y., Shirota, H., and Klinman, D. M. (2012). Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J. I. 188 (4), 1592–1599. doi:10.4049/jimmunol.1101304
Sitia, L., Bonizzi, A., Mazzucchelli, S., Negri, S., Sottani, C., Grignani, E., et al. (2021). Selective targeting of cancer-associated fibroblasts by engineered H-ferritin nanocages loaded with navitoclax. Cells 10 (2), 328. doi:10.3390/cells10020328
Song, M., Liu, T., Shi, C., Zhang, X., and Chen, X. (2016). Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-associated macrophages toward M1-like phenotype and attenuating tumor hypoxia. ACS Nano 10 (1), 633–647. doi:10.1021/acsnano.5b06779
Spranger, S., and Gajewski, T. F. (2018). Impact of oncogenic pathways on evasion of antitumour immune responses. Nat. Rev. Cancer 18 (3), 139–147. doi:10.1038/nrc.2017.117
Steele, C. W., Karim, S. A., Leach, J. D. G., Bailey, P., Upstill-Goddard, R., Rishi, L., et al. (2016). CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29 (6), 832–845. doi:10.1016/j.ccell.2016.04.014
Stephen, Z. R., and Zhang, M. (2021). Recent progress in the synergistic combination of nanoparticle-mediated hyperthermia and immunotherapy for treatment of cancer. Adv. Healthc. Mat. 10 (2), e2001415. doi:10.1002/adhm.202001415
Suek, N., Campesato, L. F., Merghoub, T., and Khalil, D. N. (2019). Targeted APC activation in cancer immunotherapy to enhance the abscopal effect. Front. Immunol. 10, 604. doi:10.3389/fimmu.2019.00604
Sun, J., Wan, Z., Xu, J., Luo, Z., Ren, P., Zhang, B., et al. (2020). Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer. Biomaterials 269, 120629. doi:10.1016/j.biomaterials.2020.120629
Sun, L., Clavijo, P. E., Robbins, Y., Patel, P., Friedman, J., Greene, S., et al. (2019). Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight 4 (7), e126853. doi:10.1172/jci.insight.126853
Sun, Q., Yang, Z., Lin, M., Peng, Y., Wang, R., Du, Y., et al. (2021). Phototherapy and anti-GITR antibody-based therapy synergistically reinvigorate immunogenic cell death and reject established cancers. Biomaterials 269, 120648. doi:10.1016/j.biomaterials.2020.120648
Sun, Y., Liu, L., Zhou, L., Yu, S., Lan, Y., Liang, Q., et al. (2020). Tumor microenvironment-triggered charge reversal polymetformin-based nanosystem Co-delivered doxorubicin and IL-12 cytokine gene for chemo-gene combination therapy on metastatic breast cancer. ACS Appl. Mat. Interfaces 12 (41), 45873–45890. doi:10.1021/acsami.0c14405
Tan, T., Hu, H., Wang, H., Li, J., Wang, Z., Wang, J., et al. (2019). Bioinspired lipoproteins-mediated photothermia remodels tumor stroma to improve cancer cell accessibility of second nanoparticles. Nat. Commun. 10 (1), 3322–22. doi:10.1038/s41467-019-11235-4
Thangam, R., Patel, K. D., Kang, H., and Paulmurugan, R. (2021). Advances in engineered polymer nanoparticle tracking platforms towards cancer immunotherapy-current status and future perspectives. Vaccines (Basel) 9 (8), 935. doi:10.3390/vaccines9080935
Trac, N., Chen, L. Y., Zhang, A., Liao, C. P., Poon, C., Wang, J., et al. (2020). CCR2-targeted micelles for anticancer peptide delivery and immune stimulation. J. Control. Release 329, 614–623. doi:10.1016/j.jconrel.2020.09.054
Trinchieri, G., and Sher, A. (2007). Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7 (3), 179–190. doi:10.1038/nri2038
Tsai, C. H., Tzeng, S. F., Hsieh, S. C., Yang, Y. C., Hsiao, Y. W., Tsai, M. H., et al. (2017). A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer. Sci. Rep. 7 (1), 15624. doi:10.1038/s41598-017-15934-0
Tsuchiya, H., and Shiota, G. (2021). Immune evasion by cancer stem cells. Regen. Ther. 17, 20–33. doi:10.1016/j.reth.2021.02.006
Tuettenberg, A., Steinbrink, K., and Schuppan, D. (2016). Myeloid cells as orchestrators of the tumor microenvironment: Novel targets for nanoparticular cancer therapy. Nanomedicine 11 (20), 2735–2751. doi:10.2217/nnm-2016-0208
Turner, J. A., Stephen-Victor, E., Wang, S., Rivas, M. N., Abdel-Gadir, A., Harb, H., et al. (2020). Regulatory T cell-derived TGF-β1 controls multiple checkpoints governing allergy and autoimmunity. Immunity 53 (6), 1202–1214. e6. doi:10.1016/j.immuni.2020.10.002
Vonderheide, R. H. (2020). CD40 agonist antibodies in cancer immunotherapy. Annu. Rev. Med. 71, 47–58. doi:10.1146/annurev-med-062518-045435
Votavova, P., Tomala, J., Subr, V., Strohalm, J., Ulbrich, K., Rihova, B., et al. (2015). Novel IL-2-poly(HPMA)nanoconjugate based immunotherapy. J. Biomed. Nanotechnol. 11 (9), 1662–1673. doi:10.1166/jbn.2015.2114
Walker, L. S., and Sansom, D. M. (2015). Confusing signals: Recent progress in CTLA-4 biology. Trends Immunol. 36 (2), 63–70. doi:10.1016/j.it.2014.12.001
Wang, S., and Zhang, Y. (2020). HMGB1 in inflammation and cancer. J. Hematol. Oncol. 13 (1), 116. doi:10.1186/s13045-020-00950-x
Wang, Y., Gong, N., Ma, C., Zhang, Y., Tan, H., Qing, G., et al. (2021). An amphiphilic dendrimer as a light-activable immunological adjuvant for in situ cancer vaccination. Nat. Commun. 12 (1), 4964. doi:10.1038/s41467-021-25197-z
Wang, Y., Shen, N., Wang, Y., Li, M., Zhang, W., Fan, L., et al. (2021). Cisplatin nanoparticles boost abscopal effect of radiation plus anti-PD1 therapy. Biomater. Sci. 9 (8), 3019–3027. doi:10.1039/d1bm00112d
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., and Sancho, D. (2019). Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20 (1), 7–24. doi:10.1038/s41577-019-0210-z
Wood, J., Yasmin-Karim, S., Mueller, R., Viswanathan, A. N., and Ngwa, W. (2020). Single radiotherapy fraction with local anti-CD40 therapy generates effective abscopal responses in mouse models of cervical cancer. Cancers (Basel) 12 (4), 1026. doi:10.3390/cancers12041026
Worrede, A., Meucci, O., and Fatatis, A. (2019). Limiting tumor seeding as a therapeutic approach for metastatic disease. Pharmacol. Ther. 199, 117–128. doi:10.1016/j.pharmthera.2019.03.007
Wu, J., Tang, C., and Yin, C. (2017). Co-delivery of doxorubicin and interleukin-2 via chitosan based nanoparticles for enhanced anti-tumor efficacy. Acta Biomater. 47, 81–90. doi:10.1016/j.actbio.2016.10.012
Xu, J., Xu, L., Wang, C., Yang, R., Zhuang, Q., Han, X., et al. (2017). Near-infrared-triggered photodynamic therapy with multitasking upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer. ACS Nano 11 (5), 4463–4474. doi:10.1021/acsnano.7b00715
Yang, W., Zhang, F., Deng, H., Lin, L., Wang, S., Kang, F., et al. (2020). Smart nanovesicle-mediated immunogenic cell death through tumor microenvironment modulation for effective photodynamic immunotherapy. ACS Nano 14 (1), 620–631. doi:10.1021/acsnano.9b07212
Ye, Q., Wang, C., Xian, J., Zhang, M., Cao, Y., and Cao, Y. (2018). Expression of programmed cell death protein 1 (PD-1) and indoleamine 2, 3-dioxygenase (Ido) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer. Hum. Pathol. 75, 81–90. doi:10.1016/j.humpath.2018.02.004
Yu, Y., Shen, M., Song, Q., and Xie, J. (2018). Biological activities and pharmaceutical applications of polysaccharide from natural resources: A review. Carbohydr. Polym. 183, 91–101. doi:10.1016/j.carbpol.2017.12.009
Yue, F. Y., Geertsen, R., Hemmi, S., Burg, G., Pavlovic, J., Laine, E., et al. (1999). IL-12 directly up-regulates the expression of HLA class I, HLA class II and ICAM-1 on human melanoma cells: A mechanism for its anti-tumor activity? Eur. J. Immunol. 29 (6), 1762–1773. doi:10.1002/(sici)1521-4141(199906)29:06<1762::aid-immu1762>3.0.co;2-f
Zamorina, S. A., Shardina, K. Y., Timganova, V. P., Bochkova, M. S., Nechaev, A. I., Khramtsov, P. V., et al. (2020). Effect of graphene oxide nanoparticles on differentiation of myeloid suppressor cells. Bull. Exp. Biol. Med. 170 (1), 84–87. doi:10.1007/s10517-020-05009-y
Zhang, H., Tang, W. L., Kheirolomoom, A., Fite, B. Z., Wu, B., Lau, K., et al. (2020). Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy. J. Control. Release 330, 1080–1094. doi:10.1016/j.jconrel.2020.11.013
Zhang, Y., Elechalawar, C. K., Hossen, M. N., Francek, E. R., Dey, A., Wilhelm, S., et al. (2021). Gold nanoparticles inhibit activation of cancer-associated fibroblasts by disrupting communication from tumor and microenvironmental cells. Bioact. Mat. 6 (2), 326–332. doi:10.1016/j.bioactmat.2020.08.009
Zheng, D., Wan, C., Yang, H., Xu, L., Dong, Q., Du, C., et al. (2020). Her2-targeted multifunctional nano-theranostic platform mediates tumor microenvironment remodeling and immune activation for breast cancer treatment. Int. J. Nanomedicine 15, 10007–10028. doi:10.2147/ijn.s271213
Zheng, L., Hu, X., Wu, H., Mo, L., Xie, S., Li, J., et al. (2020). In vivo monocyte/macrophage-hitchhiked intratumoral accumulation of nanomedicines for enhanced tumor therapy. J. Am. Chem. Soc. 142 (1), 382–391. doi:10.1021/jacs.9b11046
Zhou, N., Velez, M. A., Owen, D., and Lisberg, A. E. (2020). Immune-related adverse events (irAEs): Implications for immune checkpoint inhibitor therapy. J. Natl. Compr. Canc. Netw. 18 (9), 1287–1290. doi:10.6004/jnccn.2020.7640
Zhou, T., Liang, X., Wang, P., Hu, Y., Qi, Y., Jin, Y., et al. (2020). A hepatocellular carcinoma targeting nanostrategy with hypoxia-ameliorating and photothermal abilities that, combined with immunotherapy, inhibits metastasis and recurrence. ACS Nano 14 (10), 12679–12696. doi:10.1021/acsnano.0c01453
Zhou, Z., Wu, H., Yang, R., Xu, A., Zhang, Q., Dong, J., et al. (2020). GSH depletion liposome adjuvant for augmenting the photothermal immunotherapy of breast cancer. Sci. Adv. 6 (36), eabc4373. doi:10.1126/sciadv.abc4373
Zhu, N., Lv, X., Wang, Y., Li, J., Liu, Y., Lu, W., et al. (2016). Comparison of immunoregulatory effects of polysaccharides from three natural herbs and cellular uptake in dendritic cells. Int. J. Biol. Macromol. 93 (1), 940–951. doi:10.1016/j.ijbiomac.2016.09.064
Keywords: nanomaterials, immunotherapy, abscopal effect, metastatic cancer, immune cells
Citation: Xia Y, Yang R, Zhu J, Wang H, Li Y, Fan J and Fu C (2022) Engineered nanomaterials trigger abscopal effect in immunotherapy of metastatic cancers. Front. Bioeng. Biotechnol. 10:890257. doi: 10.3389/fbioe.2022.890257
Received: 05 March 2022; Accepted: 14 October 2022;
Published: 26 October 2022.
Edited by:
Alenka Zvonar Pobirk, University of Ljubljana, SloveniaReviewed by:
Ivana Drvenica, Institute for Medical Research, University of Belgrade, SerbiaNuray bayar Muluk, Kırıkkale University, Turkey
Stefano Luin, Scuola Normale Superiore of Pisa, Italy
Copyright © 2022 Xia, Yang, Zhu, Wang, Li, Fan and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Changfeng Fu, ZnVjZkBqbHUuZWR1LmNu